haloperidol and Acute Disease studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Research Excerpts

Excerpt	Relevance	Reference
"This study was a comparative investigation of the clinical efficacy and safety of intramuscular (IM) olanzapine, IM haloperidol, and IM levomepromazine in acute agitated patients with schizophrenia."	9.19	A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. ( Gen, K; Suzuki, H; Takahashi, Y, 2014)
" Previous studies have demonstrated that IM ziprasidone is efficacious and safe for treatment of agitation in schizophrenia."	9.17	Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. ( Deng, H; Gao, C; Karayal, ON; Li, K; Pan, S; Shi, J; Shu, L; Tang, H; Vanderburg, D; Wang, G; Wang, X; Xie, S; Xu, X; Zhang, H; Zhao, J, 2013)
"Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features."	9.14	Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. ( Alphs, L; Cohen, M; Kane, JM; Panagides, J; Zhao, J, 2010)
"This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder."	9.12	Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. ( Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E, 2006)
"To determine if any of five second-generation antipsychotics or haloperidol is more effective in treating acutely ill patients with schizophrenia, schizoaffective disorder or schizophreniform disorder."	9.12	Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. ( Charles, R; Hasan, SM; Joseph, MD; McCue, RE; Orendain, G; Urcuyo, L; Waheed, R, 2006)
" Accordingly, the hypothesis of whether 1-year relapse rate in first-episode schizophrenia under maintenance treatment with risperidone is lower compared to haloperidol in low dose was tested."	9.12	Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Bechdolf, A; Bender, S; Buchkremer, G; Degner, D; Eickhoff, M; Falkai, P; Gaebel, W; Häfner, H; Jäger, M; Jockers-Scherübl, MC; Klimke, A; Klingberg, S; Köpcke, W; Kühn, KU; Lemke, M; Maier, W; Möller, HJ; Ohmann, C; Riesbeck, M; Salize, HJ; Schlösser, R; Schmidt, LG; Schmitt, A; Schneider, F; von Wilmsdorff, M; Wölwer, W, 2007)
"We conducted a prospective double-blind study of accelerated dose titration of olanzapine in the treatment of newly admitted acutely agitated patients with schizophrenia."	9.11	Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. ( Ahl, J; Kinon, BJ; McMullen, E; Rotelli, MD, 2004)
"To compare the efficacy and tolerability of sequential IM/oral ziprasidone with haloperidol in acute exacerbation of schizophrenia or schizoaffective disorder."	9.11	Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. ( Benattia, I; Brook, S; Romano, SJ; Siu, CO; Walden, J, 2005)
"Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile."	9.10	Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002)
"Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia."	9.10	Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. ( Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A, 2003)
" haloperidol during the first 24 hours of treatment of acute schizophrenia."	9.10	Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. ( Alaka, K; Battaglia, J; Birkett, M; Bitter, I; Breier, A; Chouinard, G; Ferchland-Howe, I; Jones, B; Lindborg, SR; Meehan, K; Morris, PL; Pickard, A; Roth, J; Taylor, CC; Wright, P, 2003)
"An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia."	9.10	A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002)
"The aim of this study was to investigate the effect of reduced haloperidol, the main metabolite of the antipsychotic drug haloperidol, on psychopathology improvement and extrapyramidal adverse effects in acute schizophrenia."	9.09	Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. ( Braun, V; Meyer, FP; Neuhof, S; Ulrich, S, 1999)
"Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias."	9.09	Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001)
"The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia."	9.09	Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001)
"After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3."	9.07	Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. ( Hogarty, GE; McEvoy, JP; Steingard, S, 1991)
"Eighty-seven newly admitted inpatients with schizophrenia were randomized to receive 10, 30, or 80 mg/d of oral haloperidol."	9.07	Dosage of haloperidol for schizophrenia. ( Borenstein, M; Doddi, S; Karajgi, B; Rifkin, A; Wachspress, M, 1991)
"Seventy-one patients were entered into a multicentre, double-blind randomized study to compare the efficacy and safety of remoxipride with those of haloperidol in the acute treatment of schizophrenia or schizophreniform disorder."	9.06	A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia. ( den Boer, JA; Huisman, J; Ohrvik, J; Ravelli, DP; Verhoeven, WM; Westenberg, HG, 1990)
"The efficacy and safety of remoxipride in the treatment of schizophrenia were compared with those of haloperidol in a multicentre double-blind 6-week study which was randomized with a parallel group design and was preceded by a washout period."	9.06	Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. ( Chanas, A; Deo, R; Edwards, JG; Levine, S; Mitchell, M; Plant, I; Rastogi, SC; Soni, S, 1990)
"Zetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia."	9.05	Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia. ( Dubini, A; Freeman, HL; Levine, S; Silverstone, T, 1984)
"To determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia."	8.89	Haloperidol dose for the acute phase of schizophrenia. ( Adams, CE; Donnelly, L; Rathbone, J, 2013)
"To estimate the clinical effects of zuclopenthixol acetate for the management of acute aggression or violence thought to be due to serious mental illnesses, in comparison to other drugs used to treat similar conditions."	8.88	Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. ( Gibson, RC; Gunadasa, S; Jayakody, K; Kumar, A, 2012)
"Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)."	8.85	The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009)
"Pooled data from two 52-week, randomized, double-blind, multicenter, comparative trials of aripiprazole and haloperidol in acutely ill patients with schizophrenia were analyzed."	8.84	Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. ( Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W, 2007)
"The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database."	8.82	An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003)
"The primary goal of this review is to determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia."	8.81	Haloperidol dose for the acute phase of schizophrenia. ( Adams, CE; Hamill, KM; Marti, J; Roque, M; Waraich, PS, 2002)
"Haloperidol is the most commonly used antipsychotic drug in the therapy of acute schizophrenia."	8.80	The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. ( Brosz, M; Meyer, FP; Ulrich, S; Wurthmann, C, 1998)
"A nondiabetic young male patient in hypomanic phase of bipolar disorder on maintenance treatment with sodium valproate, developed transient episode of acute pancreatitis and diabetic ketoacidosis after addition of chlorpromazine and halopridol."	7.72	Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol. ( Gupta, SB; Laghate, VD, 2004)
"Twenty-nine hospitalized patients suffering acute exacerbations of schizophrenia were treated for 2 weeks with fixed daily oral doses of haloperidol prospectively calculated to achieve a haloperidol plasma concentration of either 8-18 ng/ml or 25-35 ng/ml."	7.68	Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. ( Arndt, SV; Coryell, WH; Kelly, MW; Miller, DD; Perry, PJ, 1990)
"Forty-four male, neuroleptic-free, acutely psychotic patients with at least one diagnosis of schizophrenia among 11 diagnostic systems, and 28 healthy controls, underwent measurement of prolactin (PRL) concentrations before and after intravenous administration of haloperidol (0."	7.68	Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems. ( Copolov, DL; Hassett, A; Keks, NA; Kulkarni, J; Mackie, B; McGorry, P; McLaughlin, M; Rubin, RT; Singh, BS; van Riel, R, 1990)
" Both groups reported insomnia as the most common treatment-emergent adverse event, and no serious adverse event was reported."	6.79	A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. ( Chan, HY; Chen, CK; Chen, JJ; Chen, YS; Chou, SY; Ree, SC; Su, LW, 2014)
" Using either a slower dose-titration or a high, single loading dose followed by a low maintenance dosing may have offered the possibility to obtain a good antipsychotic effect together with low incidence of EPS."	6.70	Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. ( Bischoff, S; Gerebtzoff, A; Möller, HJ; Volz, HP, 2002)
"In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ."	6.70	Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001)
"This 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia."	6.69	Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. ( Fleurot, O; Puech, A; Rein, W, 1998)
"D-Fenfluramine was administered to 22 young, acutely ill schizophrenics (11 females and 11 males) after 4 weeks of haloperidol treatment."	6.69	Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. ( Czobor, P; Horácek, J; Libiger, J; Mohr, P; Motlová, L, 1999)
"The relationship between Taq1 A polymorphism of dopamine D(2) receptor (DRD(2)) gene and extrapyramidal adverse effects of bromperidol and nemonapride, which are both antipsychotic drugs with selective and potent DRD(2) antagonistic property, was investigated in Japanese schizophrenic inpatients."	6.69	No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. ( Kaneko, S; Kondo, T; Mihara, K; Nagashima, U; Ono, S; Otani, K; Suzuki, A, 2000)
"Five fixed doses of the atypical antipsychotic "Seroquel" (quetiapine) were evaluated to delineate a dose-response relationship, as measured by changes from baseline in Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and Modified Scale for the Assessment of Negative Symptoms (SANS) summary scores, and to compare efficacy and tolerability opposite placebo and haloperidol."	6.68	Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. ( Arvanitis, LA; Miller, BG, 1997)
"Haloperidol treated patients reported more tiredness and drowsiness than remoxipride treated patients."	6.67	A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. ( Beckmann, H; Bunse, J; Dittmann, V; Klieser, E; König, P; Laux, G; Schöny, HW; Schröder, HG; Schubert, H; Unterweger, B, 1990)
"When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1."	6.53	Droperidol for psychosis-induced aggression or agitation. ( Khokhar, MA; Rathbone, J, 2016)
"Delirium is common in acutely ill patients and can result in substantial morbidity if left untreated."	6.44	Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. ( Battistone, S; Devlin, JW; Fong, JJ; Rea, RS, 2007)
"Aripiprazole is a novel antipsychotic with a unique mechanism of action."	6.42	Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. ( Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E, 2003)
"Haloperidol was stopped and intravenous clonazepam 5mg/kg was begun."	5.36	[Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up]. ( Askenazy, F; Benoit, M; Dor, E; Dupuis, G; Myquel, M; Seddiki, Y; Serret, S, 2010)
"With the background of a number of meta-analyses on the optimal neuroleptic dosages [1,2] the average daily dosage for the treatment of acute schizophrenic episodes recommended in the internal treatment guidelines of our psychiatric clinic was reduced from 24 mg to 15 mg haloperidol equivalent."	5.31	["More is less": a retrospective study of haloperidol dosages in acute schizophrenia]. ( Kissling, W; Kockott, G; Müller, R, 2000)
"The encephalopathy was worsened by hyperthermia, dehydration, and reintroduction of haloperidol, 5 days after the first discontinuation of the neuroleptic."	5.30	[Acute encephalomyopathy and persistent cerebellar syndrome after lithium salt and haloperidol poisoning]. ( de Barsy, T; Delbecq, J; Depré, A; Ghariani, S; Gille, M; Piéret, F; Saussu, F, 1997)
"This study was a comparative investigation of the clinical efficacy and safety of intramuscular (IM) olanzapine, IM haloperidol, and IM levomepromazine in acute agitated patients with schizophrenia."	5.19	A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. ( Gen, K; Suzuki, H; Takahashi, Y, 2014)
" Previous studies have demonstrated that IM ziprasidone is efficacious and safe for treatment of agitation in schizophrenia."	5.17	Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. ( Deng, H; Gao, C; Karayal, ON; Li, K; Pan, S; Shi, J; Shu, L; Tang, H; Vanderburg, D; Wang, G; Wang, X; Xie, S; Xu, X; Zhang, H; Zhao, J, 2013)
"Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features."	5.14	Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. ( Alphs, L; Cohen, M; Kane, JM; Panagides, J; Zhao, J, 2010)
"This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder."	5.12	Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. ( Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E, 2006)
"To determine if any of five second-generation antipsychotics or haloperidol is more effective in treating acutely ill patients with schizophrenia, schizoaffective disorder or schizophreniform disorder."	5.12	Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. ( Charles, R; Hasan, SM; Joseph, MD; McCue, RE; Orendain, G; Urcuyo, L; Waheed, R, 2006)
"Acutely agitated patients with schizophrenia or schizoaffective disorder treated with aripiprazole IM or haloperidol IM demonstrated similar effective and safe transition to their respective oral formulations."	5.12	Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. ( Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL, 2007)
" Accordingly, the hypothesis of whether 1-year relapse rate in first-episode schizophrenia under maintenance treatment with risperidone is lower compared to haloperidol in low dose was tested."	5.12	Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Bechdolf, A; Bender, S; Buchkremer, G; Degner, D; Eickhoff, M; Falkai, P; Gaebel, W; Häfner, H; Jäger, M; Jockers-Scherübl, MC; Klimke, A; Klingberg, S; Köpcke, W; Kühn, KU; Lemke, M; Maier, W; Möller, HJ; Ohmann, C; Riesbeck, M; Salize, HJ; Schlösser, R; Schmidt, LG; Schmitt, A; Schneider, F; von Wilmsdorff, M; Wölwer, W, 2007)
"We conducted a prospective double-blind study of accelerated dose titration of olanzapine in the treatment of newly admitted acutely agitated patients with schizophrenia."	5.11	Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. ( Ahl, J; Kinon, BJ; McMullen, E; Rotelli, MD, 2004)
" This study assessed the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol)."	5.11	Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. ( Ascher-Svanum, H; Kinon, BJ; Stensland, M; Zhao, Z, 2005)
"To compare the efficacy and tolerability of sequential IM/oral ziprasidone with haloperidol in acute exacerbation of schizophrenia or schizoaffective disorder."	5.11	Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. ( Benattia, I; Brook, S; Romano, SJ; Siu, CO; Walden, J, 2005)
"We aimed to compare clinical outcomes, health-related quality of life (HRQOL) and work status associated with olanzapine and haloperidol treatment in patients with bipolar disorder."	5.10	Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. ( Breier, A; Edgell, ET; Gandhi, G; Haro, JM; Namjoshi, MA; Shi, L; Tohen, M; Zhang, F, 2002)
"Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile."	5.10	Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002)
"The efficacy of ritanserin to obtain a better improvement in patients with mania seems to support the 5-HT hypothesis of bipolar disorder."	5.10	Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. ( Akhondzadeh, S; Amini, H; Mohajari, H; Reza Mohammadi, M, 2003)
"Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia."	5.10	Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. ( Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A, 2003)
" haloperidol during the first 24 hours of treatment of acute schizophrenia."	5.10	Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. ( Alaka, K; Battaglia, J; Birkett, M; Bitter, I; Breier, A; Chouinard, G; Ferchland-Howe, I; Jones, B; Lindborg, SR; Meehan, K; Morris, PL; Pickard, A; Roth, J; Taylor, CC; Wright, P, 2003)
"An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia."	5.10	A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002)
"This 3-week randomized, double-blind, placebo-controlled study included 156 bipolar disorder patients with a current manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol."	5.10	Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. ( Bowden, CL; Ghaemi, SN; Grossman, F; Okamoto, A; Sachs, GS, 2002)
"The aim of this study was to investigate the effect of reduced haloperidol, the main metabolite of the antipsychotic drug haloperidol, on psychopathology improvement and extrapyramidal adverse effects in acute schizophrenia."	5.09	Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. ( Braun, V; Meyer, FP; Neuhof, S; Ulrich, S, 1999)
"Thirty-one consenting acute inpatient subjects between ages 19 and 66 years with a DSM-III-R clinical diagnosis of bipolar disorder, manic with psychotic features were entered into this double-blind study and were randomly assigned to receive either haloperidol 25 mg/day or haloperidol 5 mg for the 3-week study."	5.09	Pretreatment plasma HVA and haloperidol response in acute mania. ( Bebe, R; Chang, WH; Charles, O; Chou, JC; Cooper, TB; Czobor, P; Lane, HY; Stone, DL; Tuma, I, 2000)
"Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias."	5.09	Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001)
"The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia."	5.09	Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001)
"After a < or = 1-day screening period, 36 consecutive hospitalized patients with bipolar disorder, manic or mixed phase and with psychotic features, were randomly assigned to receive either divalproex 20 mg/kg/day or haloperidol 0."	5.08	A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. ( Bennett, JA; Keck, PE; McElroy, SL; Stanton, SP; Strakowski, SM; Tugrul, KC, 1996)
"In a double-blind, prospective study, 2 mg of intramuscular lorazepam and 5 mg of intramuscular haloperidol were equally effective in controlling aggression, agitation, and assaultive behavior."	5.07	Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. ( Flowers, E; Glassman, R; Miyawaki, E; Rood, L; Salzman, C; Solomon, D; Thayer, S, 1991)
"After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3."	5.07	Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. ( Hogarty, GE; McEvoy, JP; Steingard, S, 1991)
"Eighty-seven newly admitted inpatients with schizophrenia were randomized to receive 10, 30, or 80 mg/d of oral haloperidol."	5.07	Dosage of haloperidol for schizophrenia. ( Borenstein, M; Doddi, S; Karajgi, B; Rifkin, A; Wachspress, M, 1991)
"Seventy-one patients were entered into a multicentre, double-blind randomized study to compare the efficacy and safety of remoxipride with those of haloperidol in the acute treatment of schizophrenia or schizophreniform disorder."	5.06	A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia. ( den Boer, JA; Huisman, J; Ohrvik, J; Ravelli, DP; Verhoeven, WM; Westenberg, HG, 1990)
"The efficacy and safety of remoxipride in the treatment of schizophrenia were compared with those of haloperidol in a multicentre double-blind 6-week study which was randomized with a parallel group design and was preceded by a washout period."	5.06	Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. ( Chanas, A; Deo, R; Edwards, JG; Levine, S; Mitchell, M; Plant, I; Rastogi, SC; Soni, S, 1990)
"A search of multiple electronic databases (through November 2018) was conducted for all placebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizophrenia symptoms."	5.05	Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. ( Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020)
"Zetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia."	5.05	Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia. ( Dubini, A; Freeman, HL; Levine, S; Silverstone, T, 1984)
"Pimozide and haloperidol were found to be equally effective in the treatment of acute schizophrenia in a double-blind clinical trial involving 22 patients."	5.05	The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. ( Ball, R; Chin, CN; Cookson, J; Gould, S; Jacobs, D; Lader, S; Silverstone, T, 1984)
"To determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia."	4.89	Haloperidol dose for the acute phase of schizophrenia. ( Adams, CE; Donnelly, L; Rathbone, J, 2013)
"Treatment of acute mania with second-generation antipsychotics has been claimed to involve a lower risk of switch to depression than haloperidol."	4.89	Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. ( Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E, 2013)
"To estimate the clinical effects of zuclopenthixol acetate for the management of acute aggression or violence thought to be due to serious mental illnesses, in comparison to other drugs used to treat similar conditions."	4.88	Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. ( Gibson, RC; Gunadasa, S; Jayakody, K; Kumar, A, 2012)
"Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)."	4.85	The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009)
"Pooled data from two 52-week, randomized, double-blind, multicenter, comparative trials of aripiprazole and haloperidol in acutely ill patients with schizophrenia were analyzed."	4.84	Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. ( Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W, 2007)
"The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database."	4.82	An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003)
"The primary goal of this review is to determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia."	4.81	Haloperidol dose for the acute phase of schizophrenia. ( Adams, CE; Hamill, KM; Marti, J; Roque, M; Waraich, PS, 2002)
"Haloperidol is the most commonly used antipsychotic drug in the therapy of acute schizophrenia."	4.80	The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. ( Brosz, M; Meyer, FP; Ulrich, S; Wurthmann, C, 1998)
"Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized."	4.79	Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997)
"To compare the effectiveness of intramuscular (IM) olanzapine and typical IM antipsychotics in naturalistically treated acutely agitated patients with schizophrenia or acute mania."	3.75	Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. ( Castle, DJ; Isik, T; Karagianis, J; Kim, CY; Melamed, Y; Omar, AN; Pidrman, V; Rosales, JI; Sarosi, A; Treuer, T; Udristoiu, T, 2009)
" We report a patient with PVCM who had stridor and dyspnea for 10 days and responded to intravenous haloperidol treatment."	3.75	Paradoxical vocal cord motion--haloperidol usage in acute attack treatment. ( Alimoglu, Y; Duman, C; Isildak, H; Karaman, E; Oz, F, 2009)
" The initial doses varied widely, ranging from 1 to 30 mg, with a maximum total daily dosage of 100 mg."	3.74	Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol. ( Donlon, PT; Hopkin, J; Tupin, JP, 1979)
"A nondiabetic young male patient in hypomanic phase of bipolar disorder on maintenance treatment with sodium valproate, developed transient episode of acute pancreatitis and diabetic ketoacidosis after addition of chlorpromazine and halopridol."	3.72	Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol. ( Gupta, SB; Laghate, VD, 2004)
"Elevated cerebrospinal fluid (CSF) angiotensin I-converting enzyme (ACE) levels have been evidenced in patients with schizophrenia who have been treated with antipsychotics."	3.70	Current antipsychotic dose correlates to mononuclear cell counts in the cerebrospinal fluid of psychotic patients. ( Ahokas, A; Nikkilä, H; Rimón, R; Wahlbeck, K, 2000)
"To examine whether acute dystonia is induced by neuroleptic treatment, common marmosets were treated with haloperidol orally twice a week over 25 weeks until dystonic behavior was elicited."	3.69	The common marmoset (Callithrix jacchus) as a model for neuroleptic-induced acute dystonia. ( Fukuoka, T; Kohda, A; Matsuo, M; Nakano, M; Okuno, Y, 1997)
"The patient was a 24-year-old man with recently diagnosed schizophrenia who presented twice to a general hospital with difficulty speaking within 72 hours of increasing his dose of haloperidol."	3.69	Neuroleptic-induced laryngeal dystonia can mimic anaphylaxis. ( Ilchef, R, 1997)
" Thirty-six acutely psychotic patients receiving parenteral haloperidol were evaluated by the Brief Psychiatric Rating Scale, the Schedule for Affective Disorders and Schizophrenia-Change Version, and the Nurses' Observation Scale for Inpatient Evaluation, as well as by drug levels in plasma."	3.68	Acutely psychotic patients receiving high-dose haloperidol therapy. ( Coulter, K; Pollock, B; Reed, K; Remington, G; Voineskos, G, 1993)
"Twenty-nine hospitalized patients suffering acute exacerbations of schizophrenia were treated for 2 weeks with fixed daily oral doses of haloperidol prospectively calculated to achieve a haloperidol plasma concentration of either 8-18 ng/ml or 25-35 ng/ml."	3.68	Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. ( Arndt, SV; Coryell, WH; Kelly, MW; Miller, DD; Perry, PJ, 1990)
"Forty-four male, neuroleptic-free, acutely psychotic patients with at least one diagnosis of schizophrenia among 11 diagnostic systems, and 28 healthy controls, underwent measurement of prolactin (PRL) concentrations before and after intravenous administration of haloperidol (0."	3.68	Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems. ( Copolov, DL; Hassett, A; Keks, NA; Kulkarni, J; Mackie, B; McGorry, P; McLaughlin, M; Rubin, RT; Singh, BS; van Riel, R, 1990)
" Many such patients respond to a trial of lithium therapy; responders are usually better able to work or attend school and to live independently, and they less often show the degree of personality deterioration present in classical schizophrenia."	3.67	Acutely psychotic patients: a treatment approach. ( Cade, JR; Lippmann, S; Wagemaker, H, 1985)
"A case of agitated delirium secondary to bilateral occipital cerebral infarctions in a cancer patient was refractory to trials of large doses of intravenous psychotropic agents, but continuous intravenous infusion of haloperidol controlled agitation rapidly and safely."	3.67	Treatment of severe, refractory agitation with a haloperidol drip. ( Adams, F; Fernandez, F; Holmes, VF; Kavanaugh, JJ, 1988)
" In this retrospective study, 15 of 16 young adult patients treated only with haloperidol had such reactions within 60 hours of beginning the drug, while none of the seven patients treated with haloperidol plus prophylactic benztropine mesylate developed dystonia."	3.67	Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. ( Bakalar, NH; Boyer, WF; Lake, CR, 1987)
"The authors treated 16 outpatients and 1 inpatient who had diagnoses of schizophrenia in exacerbation with haloperidol as the sole neuroleptic agent and obtained ratings of psychopathology and serum levels of haloperidol."	3.66	Relationship of serum haloperidol levels to clinical response in schizophrenic patients. ( Arnold, KV; Earle, GM; Hollister, LE; Magliozzi, JR, 1981)
"Twenty-four patients with acute functional psychoses were treated with intramuscular haloperidol in a three-hour period."	3.65	Rapid treatment of acute psychosis. ( Anderson, WH; Catanzano, DM; Kuehnle, JC, 1976)
"Haloperidol has been shown to be effective for migraine treatment."	2.80	A Randomized Controlled Trial of Intravenous Haloperidol vs. Intravenous Metoclopramide for Acute Migraine Therapy in the Emergency Department. ( Bruner, DI; Frumkin, K; Gaffigan, ME; Pritchard, A; Wason, C, 2015)
" Both groups reported insomnia as the most common treatment-emergent adverse event, and no serious adverse event was reported."	2.79	A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. ( Chan, HY; Chen, CK; Chen, JJ; Chen, YS; Chou, SY; Ree, SC; Su, LW, 2014)
"Haloperidol was found to be significantly more efficacious in the reduction of the mania scale score at week 1."	2.78	Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. ( Capapey, J; Colom, F; Goikolea, JM; Grande, I; Torres, I; Undurraga, J; Valenti, M; Vieta, E, 2013)
"Risperidone was shown to have significant anti-manic effects which was observed as early as week 1, following start of treatment."	2.77	Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. ( Hsu, MC; Kuo, CC; Ouyang, WC; Yeh, IN, 2012)
"haloperidol in treatment of acute migraine headache in a double-blind, randomized, placebo-controlled study design."	2.72	Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. ( Honkaniemi, J; Liimatainen, S; Rainesalo, S; Sulavuori, S, 2006)
"Lorazepam alone was as effective as lorazepam plus haloperidol or lorazepam plus risperidone in this small trial."	2.72	Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. ( Currier, GW; McMullan, JT; Veser, BD; Veser, FH; Zealberg, J, 2006)
"Olanzapine-treated patients had significantly more weight gain compared with the haloperidol and risperidone groups (p < ."	2.72	A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. ( Crespo-Facorro, B; Llorca, J; Luis Vázquez-Barquero, J; Martínez-García, O; Pérez-Iglesias, R; Ramirez-Bonilla, M, 2006)
"The design consisted of 2 successive, 6-week, double-blind periods and compared flexible dosing of olanzapine (5-20 mg/d, n = 234) with haloperidol (3-15 mg/d, n = 219)."	2.71	A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. ( Azorin, JM; Baker, RW; Breier, A; Emsley, RA; Evans, AR; Goldberg, JF; Gonzalez-Pinto Arrillaga, AM; Hardy-Bayle, MC; Lawson, WB; Namjoshi, MA; Risser, RC; Tohen, M; Vieta, E; Zhang, F, 2003)
"625 mg/day) were added to a fixed dosage of haloperidol (5 mg daily)."	2.71	Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. ( Bassitt, D; Diegoli, M; Elkis, H; Gattaz, WF; Louzã, MR; Marques, AP, 2004)
" Mean score improvements at 30, 60, and 120 minutes after dosing were significant at each timepoint in both groups (p <."	2.71	Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. ( Bossie, CA; Chou, JC; Currier, GW; Feifel, D; Gharabawi, GM; Mahmoud, RA; Turkoz, I, 2004)
" According to response, dosage was then adjusted to a maximum dosage of 20 mg daily of either drug."	2.71	Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. ( Christensen, BK; Daskalakis, Z; Epstein, I; Furimsky, I; Kapur, S; Roy, P; Sanger, T; Zipursky, RB, 2005)
" Using either a slower dose-titration or a high, single loading dose followed by a low maintenance dosing may have offered the possibility to obtain a good antipsychotic effect together with low incidence of EPS."	2.70	Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. ( Bischoff, S; Gerebtzoff, A; Möller, HJ; Volz, HP, 2002)
"In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ."	2.70	Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001)
"This 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia."	2.69	Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. ( Fleurot, O; Puech, A; Rein, W, 1998)
"D-Fenfluramine was administered to 22 young, acutely ill schizophrenics (11 females and 11 males) after 4 weeks of haloperidol treatment."	2.69	Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. ( Czobor, P; Horácek, J; Libiger, J; Mohr, P; Motlová, L, 1999)
"Olanzapine-treated patients achieved a statistically significant greater improvement than haloperidol treated patients on overall measures of efficacy, including clinical response."	2.69	Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. ( Beasley, CM; Berg, PH; Lu, Y; Sanger, TM; Tollefson, GD; Tran, PV, 1999)
"The relationship between Taq1 A polymorphism of dopamine D(2) receptor (DRD(2)) gene and extrapyramidal adverse effects of bromperidol and nemonapride, which are both antipsychotic drugs with selective and potent DRD(2) antagonistic property, was investigated in Japanese schizophrenic inpatients."	2.69	No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. ( Kaneko, S; Kondo, T; Mihara, K; Nagashima, U; Ono, S; Otani, K; Suzuki, A, 2000)
"biperiden was studied in an open clinical trial in twenty-three (12 male and 11 female) patients who developed antipsychotic-induced acute akathisia as defined by the research criteria of the DSM-IV."	2.69	Intravenous biperiden in akathisia: an open pilot study. ( Ashby, CR; Hirose, S, 2000)
"Ziprasidone was associated with a lower incidence of movement disorders and a reduced requirement for anticholinergic medication during both i."	2.69	Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. ( Brook, S; Gunn, KP; Lucey, JV, 2000)
"Five fixed doses of the atypical antipsychotic "Seroquel" (quetiapine) were evaluated to delineate a dose-response relationship, as measured by changes from baseline in Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and Modified Scale for the Assessment of Negative Symptoms (SANS) summary scores, and to compare efficacy and tolerability opposite placebo and haloperidol."	2.68	Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. ( Arvanitis, LA; Miller, BG, 1997)
" Mean daily lorazepam dosage was 0."	2.67	Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. ( Gaertner, HJ; Mahal, A; Stevens, A; Stevens, I, 1992)
" In the individually treated group the dosage was determined by a senior psychiatrist at the hospital who was not involved in collecting the data of the investigation; neither the nursing staff nor the physicians involved in thus study were informed of the dosages."	2.67	[Disagreement in standardized haloperidol treatment in comparison with "adequate individual dosage" of acutely schizophrenic patients]. ( Klieser, E; Lehmann, E, 1992)
"Haloperidol treated patients reported more tiredness and drowsiness than remoxipride treated patients."	2.67	A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. ( Beckmann, H; Bunse, J; Dittmann, V; Klieser, E; König, P; Laux, G; Schöny, HW; Schröder, HG; Schubert, H; Unterweger, B, 1990)
" Dosage ratios of loxapine to haloperidol ranged from a minimum of 2."	2.66	A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. ( Tuason, VB, 1986)
"Using a double-blind experimental design, two dosage regimens of haloperidol were compared in acutely decompensated, newly admitted schizophrenic patients."	2.65	Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens. ( Greub, E; Modestin, J; Pia, M; Toffler, G, 1983)
"In a double-blind controlled study, 20 acutely psychotic inpatients were treated with different haloperidol dosage regimens."	2.65	Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. ( Depry, D; Janowsky, DS; Munson, E; Neborsky, RJ; Perel, JM, 1984)
"Clonazepam was found to be significantly more efficacious than lithium in reducing manic symptoms despite the fact that during clonazepam treatment less patients required PRNs of haloperidol."	2.65	Antimanic effect of clonazepam. ( Annable, L; Chouinard, G; Young, SN, 1983)
" Mean daily dosage was approximately 112 mg flupenthixol and 18 mg haloperidol."	2.65	Flupenthixol versus haloperidol in acute psychosis. ( Parent, M; Toussaint, C, 1983)
"Haloperidol was well tolerated by the patients; there were no serious adverse reactions."	2.65	Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens. ( Donlon, PT; Hopkin, JT; Meadow, A; Tupin, JP; Wahba, M; Wicks, JJ, 1980)
", as needed over a four-hour period (total dosage ranging from 4 to 32 mg."	2.64	Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. ( Stotsky, BA, 1977)
" Ironically, chronic use of cannabis can result in paradoxical effects, including a condition known as cannabinoid hyperemesis syndrome."	2.61	Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting. ( Forest, CP; Smith, TN; Walsh, A, 2019)
"When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1."	2.53	Droperidol for psychosis-induced aggression or agitation. ( Khokhar, MA; Rathbone, J, 2016)
"When haloperidol and midazolam were compared with olanzapine, there was some evidence the combination was superior in terms of improvement, sedation and behaviour."	2.49	Benzodiazepines for psychosis-induced aggression or agitation. ( Beck, A; Gillies, D; Rathbone, J; Sampson, S, 2013)
"Delirium is common in acutely ill patients and can result in substantial morbidity if left untreated."	2.44	Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. ( Battistone, S; Devlin, JW; Fong, JJ; Rea, RS, 2007)
"Haloperidol was superior to quetiapine in efficacy at day 21 but similar at day 84."	2.44	Quetiapine for acute mania in bipolar disorder. ( Brahm, NC; Carnahan, RM; Gutierres, SL, 2007)
"Aripiprazole is a novel antipsychotic with a unique mechanism of action."	2.42	Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. ( Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E, 2003)
"Olanzapine is a new "atypical" antipsychotic agent that belongs chemically to the thienobenzodiazepine class."	2.40	Efficacy of olanzapine: an overview of pivotal clinical trials. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997)
"Acute confusional state is a condition that is commonly encountered in many types of medical practice."	2.38	Acute confusional state. Don't mistake it for dementia. ( Petersen, RC, 1992)
"Acute dystonia can also be reliably induced in many primate species by neuroleptic treatment with comparable time course, symptomatology and pharmacological characteristics to those observed in man."	2.37	Acute dystonia induced by neuroleptic drugs. ( Jenner, P; Marsden, CD; Rupniak, NM, 1986)
"Most cases of acute dystonia are mild and easy to manage; nevertheless, some of them can be fatal because of the involvement of certain muscle groups such as the laryngeal muscles, thus requiring urgent intervention."	1.39	Is acute dystonia an emergency? Sometimes, it really is! ( Cizmeci, MN; Derinoz, O; Havali, C; Kanburoglu, MK, 2013)
"Extrapyramidal symptoms (EPSs) are common adverse effects of antipsychotics."	1.39	The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. ( Bozina, N; Mihaljević-Peles, A; Muck-Seler, D; Nikolac-Perkovic, M; Sagud, M; Vuksan-Cusa, B; Zivković, M, 2013)
"Haloperidol was stopped and intravenous clonazepam 5mg/kg was begun."	1.36	[Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up]. ( Askenazy, F; Benoit, M; Dor, E; Dupuis, G; Myquel, M; Seddiki, Y; Serret, S, 2010)
"The structure of depressive syndrome was influenced by the number of previous psychotic episodes The combination of antipsychotics and antidepressants was effective in the treatment of depressive symptoms in schizophrenic patients during the postpsychotic phase."	1.35	[Depression in schizophrenia]. ( Ivanets, NN; Kinkul'kina, MA, 2008)
"Treatment with risperidone solution orally or parenteral haloperidol until the day after admission, followed by olanzapine, successfully improved the clinical condition of the patients."	1.35	Three cases of schizophrenia for which olanzapine was effective after early acute phase. ( Inada, T; Oda, T; Yamamoto, N, 2008)
"Drug-induced delirium is a common matter in the elderly and anticholinergics, together with a number of different drugs, may significantly contribute to the delirium onset, especially in demented people."	1.34	Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient. ( Cotroneo, A; De Fazio, P; De Fazio, S; De Sarro, G; Gallelli, L; Gareri, P; Lacava, R, 2007)
"Upon treatment with diazepam and haloperidol, the psychosis subsided within three days."	1.34	[Postictal paranoid-hallucinatory psychosis in cryptogenic epilepsy]. ( Baum, P; Hermann, W; Kopf, A; Wagner, A, 2007)
"Chorea is a rare complication of polycythaemia vera."	1.33	Hemichorea associated with polycythaemia vera. ( Afsar, N; Dib, H; Günal, DI; Köseoglu, M; Midi, I, 2006)
" The main effect of the long-term administration of haloperidol seems to be an increase of cerebellar, basal ganglia and motor area metabolism."	1.32	Cerebral metabolic patterns in chronic and recent-onset schizophrenia. ( Benito, C; Desco, M; Gispert, JD; Molina, V; Palomo, T; Pascau, J; Reig, S; Santos, A; Sanz, J; Sarramea, F, 2003)
"With the background of a number of meta-analyses on the optimal neuroleptic dosages [1,2] the average daily dosage for the treatment of acute schizophrenic episodes recommended in the internal treatment guidelines of our psychiatric clinic was reduced from 24 mg to 15 mg haloperidol equivalent."	1.31	["More is less": a retrospective study of haloperidol dosages in acute schizophrenia]. ( Kissling, W; Kockott, G; Müller, R, 2000)
"After treatment of neurosyphilis, steady improvements were noted in psychotic and cognitive symptoms."	1.31	Neurosyphilis presenting as schizophrenialike psychosis. ( Ballas, C; Kohler, CG; Pickholtz, J, 2000)
"The acute phase of schizophrenia is characterized by the presence of positive, negative and affective symptoms."	1.31	Acute phase of schizophrenia: impact of atypical antipsychotics. ( Azorin, JM, 2000)
"Oral treatment with risperidone and lorazepam appears to be a tolerable and comparable alternative to intramuscular haloperidol and lorazepam for short-term treatment of agitated psychosis in patients who accept oral medications."	1.31	Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. ( Currier, GW; Simpson, GM, 2001)
"The encephalopathy was worsened by hyperthermia, dehydration, and reintroduction of haloperidol, 5 days after the first discontinuation of the neuroleptic."	1.30	[Acute encephalomyopathy and persistent cerebellar syndrome after lithium salt and haloperidol poisoning]. ( de Barsy, T; Delbecq, J; Depré, A; Ghariani, S; Gille, M; Piéret, F; Saussu, F, 1997)
"We report on a patient with schizoaffective disorder who developed unilateral akathisia."	1.30	A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep. ( Horiguchi, J; Inami, Y; Kuramoto, Y; Mizuno, S; Yamashita, H; Yamawaki, S, 1999)
"Haloperidol was the sole neuroleptic prescribed for 91."	1.29	Neuroleptic prescriptions for acutely ill geriatric patients. ( Driscoll, A; Hesse, KA; Jacobson, S, 1993)
"Cysticercosis is a parasitic disease endemic in several developing countries where people consume raw or insufficiently cooked pork."	1.28	You drive me crazy: a case report of acute psychosis and neurocysticercosis. ( Milette, PC; Shriqui, CL, 1992)
"Haloperidol and clozapine were rapidly withdrawn from a schizophrenic patient on separate occasions several months apart."	1.28	Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. ( Alphs, LD; Lee, HS, 1991)
"Rhabdomyolysis is a rarely reported complication of antipsychotic drug-induced dystonia."	1.27	Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. ( Cavanaugh, JJ; Finlayson, RE, 1984)
"A patient with long-standing Tourette's syndrome had a dramatic exacerbation of symptoms following the rapid withdrawal of haloperidol."	1.27	Clonidine in the treatment of Tourette's syndrome exacerbation due to haloperidol withdrawal. ( Max, JE; Rasmussen, SA, 1986)
"In recent years, the complex treatment of schizophrenia has been extended by the neuroleptic large-dose therapy."	1.26	[Neuroleptic large dose therapy of schizophrenias]. ( Pethö, B; Ungvári, G, 1981)
"The syndrome was not seen after thioridazine (3-7 mg/kg)."	1.26	Acute dystonia as an idiosyncratic response to neuroleptics in baboons. ( Anlezark, GM; Marsden, CD; Meldrum, BS, 1977)

Research

Studies (329)

Authors

Clinical Trials (20)

Trial Overview

Trial Outcomes

Change From Baseline in Behavioral Activity Rating Scale (BARS) at 72 Hours

Timeframe	Studies, this research(%)	All Research%
pre-1990	136 (41.34)	18.7374
1990's	71 (21.58)	18.2507
2000's	94 (28.57)	29.6817
2010's	26 (7.90)	24.3611
2020's	2 (0.61)	2.80

Authors	Studies
Bartolomei, G	1
Lorenzini, L	1
Martelli, M	1
Gambaro, E	1
Zeppegno, P	1
Gramaglia, C	1
Leucht, S	1
Crippa, A	1
Siafis, S	1
Patel, MX	1
Orsini, N	1
Davis, JM	4
Smith, TN	1
Walsh, A	1
Forest, CP	1
Zhang, H	1
Wang, G	1
Zhao, J	2
Xie, S	1
Xu, X	1
Shi, J	1
Deng, H	1
Li, K	1
Gao, C	1
Wang, X	2
Vanderburg, D	1
Pan, S	1
Tang, H	1
Shu, L	1
Karayal, ON	1
Kanburoglu, MK	1
Derinoz, O	1
Cizmeci, MN	1
Havali, C	1
Gillies, D	1
Sampson, S	1
Beck, A	1
Rathbone, J	3
Zivković, M	1
Mihaljević-Peles, A	1
Bozina, N	1
Sagud, M	1
Nikolac-Perkovic, M	1
Vuksan-Cusa, B	1
Muck-Seler, D	1
Donnelly, L	1
Adams, CE	2
Suzuki, H	1
Gen, K	1
Takahashi, Y	1
Gupta, S	1
Oosthuizen, R	1
Pulfrey, S	1
Chan, HY	1
Ree, SC	1
Su, LW	1
Chen, JJ	1
Chou, SY	1
Chen, CK	1
Chen, YS	1
Cannella, M	1
Motolese, M	1
Bucci, D	1
Molinaro, G	1
Gradini, R	1
Bruno, V	1
Nicoletti, F	1
Battaglia, G	1
Gaffigan, ME	1
Bruner, DI	1
Wason, C	1
Pritchard, A	1
Frumkin, K	1
Suzuki, K	1
Khokhar, MA	1
Peterson, E	1
Stoebner, A	1
Weatherill, J	1
Kutscher, E	1
San, L	2
Krishnakumar, P	1
Jayakrishnan, MP	1
Beegum, MN	1
Riyaz, A	1
Castle, DJ	1
Udristoiu, T	1
Kim, CY	1
Sarosi, A	1
Pidrman, V	1
Omar, AN	1
Rosales, JI	1
Melamed, Y	1
Isik, T	1
Karagianis, J	1
Treuer, T	1
Ivanets, NN	1
Kinkul'kina, MA	1
Janicak, PG	3
Glick, ID	1
Marder, SR	2
Crandall, DT	3
McQuade, RD	4
Marcus, RN	3
Eudicone, JM	1
Assunção-Talbott, S	1
Freeman, DJ	1
DiPaula, BA	1
Love, RC	1
Karaman, E	1
Duman, C	1
Alimoglu, Y	1
Isildak, H	1
Oz, F	1
Roman, AM	1
Hughes, J	1
Simmons, HF	1
Askenazy, F	1
Dor, E	1
Benoit, M	1
Dupuis, G	1
Serret, S	1
Myquel, M	1
Seddiki, Y	1
Bischoff, A	1
Hsu, WY	1
Huang, SS	1
Lee, BS	1
Chiu, NY	1
Kane, JM	5
Cohen, M	1
Alphs, L	1
Panagides, J	1
Gaebel, W	3
Riesbeck, M	2
Wölwer, W	3
Klimke, A	2
Eickhoff, M	2
von Wilmsdorff, M	2
Lemke, M	2
Heuser, I	1
Maier, W	2
Huff, W	1
Schmitt, A	2
Sauer, H	1
Riedel, M	1
Klingberg, S	2
Köpcke, W	2
Ohmann, C	2
Möller, HJ	7
Hughes, L	1
Fuller, G	1
Herrag, M	1
Sajiai, H	1
Alaoui Yazidi, A	1
Wilson, MP	1
MacDonald, K	2
Vilke, GM	2
Feifel, D	4
Ouyang, WC	1
Hsu, MC	1
Yeh, IN	1
Kuo, CC	1
Jayakody, K	1
Gibson, RC	1
Kumar, A	1
Gunadasa, S	1
Wilson, M	1
Minassian, A	1
Becker, O	1
Tallian, K	1
Cobb, P	1
Perez, R	1
Galangue, B	1
Goikolea, JM	2
Colom, F	2
Capapey, J	2
Torres, I	2
Valenti, M	2
Grande, I	2
Undurraga, J	2
Vieta, E	5
Sanchez-Moreno, J	1
Volz, HP	1
Gerebtzoff, A	1
Bischoff, S	1
Waraich, PS	1
Roque, M	1
Hamill, KM	1
Marti, J	1
Shi, L	1
Namjoshi, MA	2
Zhang, F	2
Gandhi, G	1
Edgell, ET	1
Tohen, M	3
Breier, A	5
Haro, JM	1
Carson, WH	4
Saha, AR	1
Ingenito, GG	1
Zimbroff, DL	2
Ali, MW	1
Majumdar, A	1
Appleton, RE	1
Taymeeyapradit, U	1
Kuasirikul, S	1
Desco, M	1
Gispert, JD	1
Reig, S	1
Sanz, J	1
Pascau, J	1
Sarramea, F	1
Benito, C	1
Santos, A	1
Palomo, T	1
Molina, V	1
Stock, E	3
Kaplita, S	1
Marcus, R	3
Safferman, AZ	1
Saha, A	2
Ali, M	2
Iwamoto, T	3
Wynchank, D	1
Berk, M	1
Akhondzadeh, S	2
Mohajari, H	1
Reza Mohammadi, M	1
Amini, H	2
Carlson, CD	1
Cavazzoni, PA	1
Berg, PH	3
Wei, H	1
Beasley, CM	5
Sielk, M	1
Kasper, S	1
Lerman, MN	1
Archibald, D	1
Ingenito, G	1
Pigott, T	1
Nadaoka, T	1
Awata, S	1
Uchida, N	1
Amano, N	1
Goldberg, JF	1
Gonzalez-Pinto Arrillaga, AM	1
Azorin, JM	4
Hardy-Bayle, MC	1
Lawson, WB	1
Emsley, RA	1
Baker, RW	2
Risser, RC	1
Evans, AR	1
Wright, P	3
Lindborg, SR	1
Birkett, M	3
Meehan, K	4
Jones, B	4
Alaka, K	1
Ferchland-Howe, I	1
Pickard, A	1
Taylor, CC	3
Roth, J	1
Battaglia, J	1
Bitter, I	2
Chouinard, G	6
Morris, PL	1
Louzã, MR	1
Marques, AP	1
Elkis, H	1
Bassitt, D	1
Diegoli, M	1
Gattaz, WF	3
Currier, GW	4
Chou, JC	3
Bossie, CA	1
Turkoz, I	1
Mahmoud, RA	1
Gharabawi, GM	1
Kinon, BJ	3
Ahl, J	1
Rotelli, MD	1
McMullen, E	1
Martínez Fernández, G	1
Plaza Moral, A	1
Miró Descarga, P	1
Arguís Gimeno, MJ	1
Gomar Sancho, C	1
Higashima, M	1
Takeda, T	1
Nagasawa, T	1
Hirao, N	1
Oka, T	1
Nakamura, M	1
Kitamura, M	1
Koshino, Y	1
Finch, S	1
Laghate, VD	1
Gupta, SB	1
Ascher-Svanum, H	1
Stensland, M	1
Zhao, Z	1
Brook, S	3
Walden, J	2
Benattia, I	1
Siu, CO	1
Romano, SJ	1
Storosum, JG	1
Wohlfarth, T	1
Gispen-de Wied, CC	1
Linszen, DH	1
Gersons, BP	1
van Zwieten, BJ	1
van den Brink, W	1
Kapur, S	2
Arenovich, T	1
Agid, O	1
Zipursky, R	1
Lindborg, S	1
Zipursky, RB	1
Christensen, BK	1
Daskalakis, Z	1
Epstein, I	1
Roy, P	1
Furimsky, I	1
Sanger, T	1
Bourin, M	1
Sanchez, R	1
McQuade, R	2
Carson, W	1
Abou-Gharbia, N	1
Swanink, R	1
Peitl, A	1
Vucić Peitl, M	1
Pavlović, E	1
Ljubicić, D	1
Kirpichenko, AA	1
Honkaniemi, J	1
Liimatainen, S	1
Rainesalo, S	1
Sulavuori, S	1
Veser, FH	1
Veser, BD	1
McMullan, JT	1
Zealberg, J	1
Crespo-Facorro, B	2
Pelayo-Terán, JM	1
Pérez-Iglesias, R	2
Ramírez-Bonilla, M	2
Martínez-García, O	2
Pardo-García, G	1
Vázquez-Barquero, JL	1
Jukić, I	1
Titlić, M	1
Tonkić, A	1
Dodig, G	1
Rogosić, V	1
Andrezina, R	1
Josiassen, RC	1
Oren, DA	1
Manos, G	2
Miyaoka, T	1
Yasukawa, R	1
Yasuda, H	1
Hayashida, M	1
Inagaki, T	1
Horiguchi, J	2
Milajerdi, MR	1
Tehrani-Doost, M	1
McCue, RE	1
Waheed, R	1
Urcuyo, L	1
Orendain, G	1
Joseph, MD	1
Charles, R	1
Hasan, SM	1
Llorca, J	1
Luis Vázquez-Barquero, J	1
Midi, I	1
Dib, H	1
Köseoglu, M	1
Afsar, N	1
Günal, DI	1
Gareri, P	1
De Fazio, P	1
Cotroneo, A	1
Lacava, R	1
Gallelli, L	1
De Fazio, S	1
De Sarro, G	1
Rea, RS	1
Battistone, S	1
Fong, JJ	1
Devlin, JW	1
Tamayo, JM	1
Mazzotti, G	1
Zapata, R	1
Castillo, JJ	1
Fahrer, RD	1
González-Pinto, AM	1
Brown, E	1
Brunner, E	1
Rovner, J	1
Bonett-Perrin, E	1
Brahm, NC	1
Gutierres, SL	1
Carnahan, RM	1
Daniel, DG	1
Allen, MH	1
Oren, D	1
Pikalov, AA	1
Eudicone, J	1
Pikalov, A	1
Swyzen, W	1
Fakra, E	1
Salgado-Pineda, P	1
Besnier, N	1
Blin, O	1
Reschke, RW	1
Jockers-Scherübl, MC	1
Kühn, KU	1
Bechdolf, A	1
Bender, S	1
Degner, D	1
Schlösser, R	1
Schmidt, LG	3
Jäger, M	1
Buchkremer, G	1
Falkai, P	1
Häfner, H	1
Salize, HJ	1
Schneider, F	1
Baum, P	1
Kopf, A	1
Hermann, W	1
Wagner, A	1
Yamamoto, N	1
Oda, T	1
Inada, T	1
Cesario, V	1
Lapolla, A	1
Gomez, J	1
Scott, G	1
Gross, ML	1
Ungvári, G	1
Pethö, B	1
Porsolt, RD	2
Jalfre, M	1
Schüssler, G	1
Kappes, CV	1
Müller-Oerlinghausen, B	2
Greenberg, JS	1
Brown, WA	1
Laughren, TP	1
Krantz, J	1
Extein, I	2
Pottash, AL	2
Gold, MS	2
Silverstone, T	3
Levine, S	2
Freeman, HL	1
Dubini, A	1
Neale, R	1
Gerhardt, S	1
Liebman, JM	1
Modestin, J	1
Toffler, G	1
Pia, M	1
Greub, E	1
Neborsky, RJ	1
Janowsky, DS	1
Perel, JM	1
Munson, E	3
Depry, D	3
Resnick, M	1
Burton, BT	1
Cookson, J	2
Ball, R	1
Chin, CN	1
Jacobs, D	1
Lader, S	1
Gould, S	1
Young, SN	1
Annable, L	1
Bourguignon, A	1
Monfort, JC	1
de Medeiros, P	1
Cadet, B	1
Chaneac, D	1
Swigar, ME	3
Jatlow, PI	3
Goicoechea, N	2
Opsahl, C	1
Bowers, MB	3
Lienert, GA	1
Lehmann, E	4
Brooks, SC	1
D'Angelo, L	1
Chalmeta, A	1
Ahern, G	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation[NCT02935998]	Phase 4	1,000 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
A Randomized, Open Label, Rater Blind, Flexible Dose Multi-Center Study Comparing The Efficacy And Safety Of Intramuscular Ziprasidone With Haloperidol For Three Days In Patients With Agitation Of Schizophrenia[NCT00723606]	Phase 3	376 participants (Actual)	Interventional	2008-09-30	Completed
A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Haloperidol Positive Control in Subjects With an Acute Exacerbation of Schizophrenia[NCT00156104]	Phase 3	460 participants (Actual)	Interventional	2005-07-01	Completed
Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120]	Phase 4	71 participants (Anticipated)	Interventional	2001-11-30	Completed
Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications[NCT05473741]		180 participants (Anticipated)	Observational	2023-01-09	Recruiting
Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130]		9 participants (Actual)	Interventional	2016-06-08	Terminated (stopped due to The study was terminated due to lack of enrollment.)
Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033]	Phase 4	38 participants (Actual)	Interventional	2005-03-31	Completed
Haloperidol vs Olanzapine for the Management of ICU Delirium: A Randomized Clinical Trial[NCT00833300]		200 participants (Anticipated)	Interventional	2008-06-30	Terminated
One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia[NCT00159081]	Phase 4	159 participants (Actual)	Interventional	2000-11-30	Completed
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936]	Phase 4	16 participants (Actual)	Interventional	2005-12-31	Completed
Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715]	Phase 4	23 participants (Actual)	Interventional	2004-03-31	Completed
Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study[NCT02318290]		54 participants (Actual)	Observational	2015-01-31	Completed
Opioid Withdrawal Symptoms in Critically Ill Patients[NCT03374722]		55 participants (Actual)	Observational	2018-01-01	Completed
Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults[NCT03435614]		29 participants (Actual)	Observational	2018-02-26	Completed
Assessing Current Analgesia and Sedation Weaning Practices in Adult Critically Ill Patients[NCT04422808]		2,437 participants (Actual)	Observational	2021-06-01	Completed
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone[NCT00096863]	Phase 2	102 participants (Actual)	Interventional	2004-12-31	Completed
An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia[NCT00797277]	Phase 3	67 participants (Actual)	Interventional	2006-07-31	Completed
The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00253149]	Phase 3	158 participants (Actual)	Interventional		Completed
A Randomized, Double-Blind, Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Combined With Low Dose of Haloperidol in the Treatment of Schizophrenic Disorder[NCT00998608]	Phase 4	88 participants (Actual)	Interventional	2007-08-31	Terminated (stopped due to terminated)
Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder[NCT00231985]	Phase 2	122 participants (Actual)	Interventional	2005-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

BARS measures the degree of agitated behavior using a 7-point scale describing increasing levels of activity (1 =difficult or unable to rouse; 2 = asleep but responds normally to verbal or physical contact; 3 = drowsy, appears sedated; 4 = quiet and awake [normal level of activity]; 5 = signs of overt [physical or verbal] activity, calms down with instructions; 6 = extremely or continuously active, not requiring restraint; 7 = violent, requires restraint. (NCT00723606)
Timeframe: Baseline, 72 hours

Change From Baseline in BPRS Agitation Subscale Score at 72 Hours

Intervention	scores on a scale (Least Squares Mean)
Ziprasidone	-0.93
Haloperidol	-1.06

The BPRS agitation subscale score was composed of 4 questions (questions 2, 6, 10, 17). The BPRS agitation subscale score was obtained by summing the relevant individual items. Total possible score range=4 to 28. Change: score at final visit minus score at baseline. (NCT00723606)
Timeframe: Baseline, 72 hours

Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Scores at 72 Hours

Intervention	scores on a scale (Least Squares Mean)
Ziprasidone	-6.97
Haloperidol	-7.45

BPRS is an 18-item clinician rated scale with 11 general symptom items, 5 positive-symptom items, and 2 negative symptom items scored on a 7-point scale (1=not present and 7=extremely severe), with higher score indicating greater severity of symptom. Total possible score range=18 to 126. Change: score at final visit minus score at baseline. (NCT00723606)
Timeframe: Baseline, 72 hours

Change From Baseline in Clinical Global Impressions Severity (CGI-S) Score at 72 Hours

Intervention	scores on a scale (Least Squares Mean)
Ziprasidone	-17.32
Haloperidol	-18.44

CGI-S: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline. (NCT00723606)
Timeframe: Baseline, 72 hours

Clinical Global Impression-Improvement (CGI-I) Score at 72 Hours

Intervention	scores on a scale (Least Squares Mean)
Ziprasidone	-1.18
Haloperidol	-1.21

CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. (NCT00723606)
Timeframe: 72 hours

BPRS Agitation Subscale Response at 72 Hours

Intervention	scores on a scale (Least Squares Mean)
Ziprasidone	2.52
Haloperidol	2.55

The BPRS agitation subscale score was composed of 4 questions (questions 2, 6, 10, 17). The BPRS agitation subscale score was obtained by summing the relevant individual items. Total possible score range=4 to 28. A response was defined as a > 30 percent reduction from baseline in BPRS agitation subscale score. (NCT00723606)
Timeframe: 72 hours

Change in Body Mass Index (BMI)

Intervention	participants (Number)
	Response	No Response
Haloperidol	155	29
Ziprasidone	149	39

A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Change in Glucose Metabolism

Intervention	kg/m^2 (Mean)
Aripiprazole	-0.52
Placebo	0.03

A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Change in Insulin Resistance

Intervention	min^-1 (Mean)
Aripiprazole	0.003
Placebo	-0.005

A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Change in Total Cholesterol

Intervention	HOMA score (Mean)
Aripiprazole	0.6
Placebo	0.65

A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Change in Triglycerides

Change in Weight

Intervention	mg/dL (Mean)
Aripiprazole	-15.3
Placebo	5.6

Intervention	mg/dL (Mean)
Aripiprazole	-5.9
Placebo	-7.3

A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8

Change From Baseline in Body Mass Index (BMI)

Intervention	kg (Mean)
Aripiprazole	-1.5
Placebo	0.3

Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Fasting Total Cholesterol

Intervention	kg/m^2 (Mean)
Aripiprazole	-0.4
Placebo	0.3

Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

Intervention	mg/dL (Mean)
Aripiprazole	-3
Placebo	9

Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Low-density Lipoprotein (LDL)

Intervention	mg/dL (Mean)
Aripiprazole	0.4
Placebo	0.6

Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Triglycerides

Intervention	mg/dL (Mean)
Aripiprazole	-0.2
Placebo	3.1

Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Waist-hip Ratio (WHR)

Intervention	mg/dL (Mean)
Aripiprazole	-51.7
Placebo	47.6

Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Weight (Lbs)

Intervention	cm (Mean)
Aripiprazole	0.0
Placebo	0.0

Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Clinical Symptoms

Intervention	lbs (Mean)
Aripiprazole	-2.9
Placebo	2.1

The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks

Mean Number of Drinking Days Per Week

Intervention	Units on a scale (Mean)
QUET	65.5

Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks

Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Criteria

Intervention	Drinking Days per Week (Mean)
QUET	2.7

"Percentage of daily assessments associated with each of the following signs and symptoms experienced by patients with and without OIWS (Restlessness (Richmond Agitation-Sedation scale = 1), Agitation (RASS > 1), Anxiety, Hallucinations, Insomnia/sleep disturbance (< 4 hours of continuous sleep), Mydriasis (Pupil diameter > 2 mm) and systolic blood pressure (SBP) > 140 mmHg. These assessments were performed once daily.~Note that for the group of patients experiencing IWS, the data on signs and symptoms are limited to the assessment on the day that patients experienced OIWS.~The signs and symptoms presented (Restlessness; Agitation; Anxiety, Hallucinations, Insomnia/sleep disturbance; mydriasis; SBP > 140) were selected based on a > 15 % absolute difference between both groups which was judged to be clinically significant." (NCT03435614)
Timeframe: From first day of opioid dose reduction until transfer out of Intensive care unit (ICU) or a maximum of 14 days, including one further assessment post-ICU transfer

Change of the Agitation-Calmness Evaluation Scale (ACES) Score From Baseline to 120 Minutes After 1st Injection

Intervention	percentage of assessments (Number)
	Restlessness (RASS = 1)	Agitation (RASS > 1)	Anxiety	Hallucinations	Insomnia/Sleep disturbance (< 4 hours of continuous sleep)	Mydriasis (pupil size > 2mm)	Systolic Blood Pressure (SBP) > 140 mmHg
IWS Negative	13.6	4.9	30.6	11.2	21.4	77.8	53
IWS Positive	28.6	28.6	57.1	28.6	66.7	100	85.7

Agitation was further assessed by the Agitation Calmness Evaluation Scale (ACES) (Copyright 1998, Eli Lilly and Company), a single-item scale developed by Eli Lilly and Company on which 1 indicates marked agitation; 2, moderate agitation; 3, mild agitation; 4, normal; 5, mild calmness; 6, moderate calmness; 7, marked calmness; 8, deep sleep; and 9, unable to be aroused. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection

The Change of the Positive and Negative Symptom Scale Excited Component (PANSS-EC) Score From Baseline to 120 Minutes After First Injection

Intervention	units on a scale (Mean)
1. IM Olanzapine	2.14
2. IM Haloperidol Pus Lorazepam	2.23

The primary efficacy measure was PANSS-EC, which was derived from the PANSS by its originators using a principal-components factor analysis, and includes the items of tension, uncooperativeness, hostility, poor impulse control and excitement.22 The score of each item ranges from 1 (normal) to 7 (most severe), with a total sum score ranging from 5 to 35. The changes in PANSS-EC from baseline to 2 hours after the first injection were compared. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection

Article	Year
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper	2013
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper	2013
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper	2013
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper	2013
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Human psychopharmacology, 2014, Volume: 29, Issue:1 Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Inje	2014
A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido	2014
A Randomized Controlled Trial of Intravenous Haloperidol vs. Intravenous Metoclopramide for Acute Migraine Therapy in the Emergency Department. The Journal of emergency medicine, 2015, Volume: 49, Issue:3 Topics: Acute Disease; Adolescent; Adult; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Double-Bli	2015
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:3 Topics: Acute Disease; Administration, Oral; Adult; Benzodiazepines; Disease Management; Female; Haloperidol	2010
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:2 Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Dibenzocycloheptenes; Double-Blind Method; Female; Ha	2010
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy;	2011
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy;	2011
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy;	2011
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy;	2011
Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. International journal of psychiatry in clinical practice, 2012, Volume: 16, Issue:3 Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Wei	2012
Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013, Volume: 23, Issue:4 Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Haloperidol; Humans; Random	2013
Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. European archives of psychiatry and clinical neuroscience, 2002, Volume: 252, Issue:2 Topics: Acute Disease; Antipsychotic Agents; Corpus Striatum; Dibenzoxazepines; Dopamine D2 Receptor Antagon	2002
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. International clinical psychopharmacology, 2002, Volume: 17, Issue:5 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method;	2002
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:9 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Doubl	2002
Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2002, Volume: 85, Issue:12 Topics: Acute Disease; Adult; Brief Psychiatric Rating Scale; Clopenthixol; Dose-Response Relationship, Drug	2002
Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial. Human psychopharmacology, 2003, Volume: 18, Issue:4 Topics: Acute Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Disease	2003
Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. BMC psychiatry, 2003, Jun-19, Volume: 3 Topics: Acute Disease; Adult; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Haloperidol;	2003
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology, 2003, Volume: 6, Issue:4 Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol;	2003
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Archives of general psychiatry, 2003, Volume: 60, Issue:12 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relatio	2003
Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2003, Volume: 48, Issue:11 Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatr	2003
Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophrenia research, 2004, Feb-01, Volume: 66, Issue:2-3 Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Drug	2004
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Cluster Analysis	2004
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. The American journal of emergency medicine, 2004, Volume: 22, Issue:3 Topics: Acute Disease; Administration, Oral; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepin	2004
Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia. European psychiatry : the journal of the Association of European Psychiatrists, 2004, Volume: 19, Issue:6 Topics: Acute Disease; Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; D	2004
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC psychiatry, 2005, Jan-13, Volume: 5 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido	2005
Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology, 2005, Volume: 178, Issue:4 Topics: Acute Disease; Administration, Oral; Adult; Affective Disorders, Psychotic; Brief Psychiatric Rating	2005
Evidence for onset of antipsychotic effects within the first 24 hours of treatment. The American journal of psychiatry, 2005, Volume: 162, Issue:5 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rat	2005
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2005, Volume: 50, Issue:8 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Dose-Respo	2005
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. The British journal of psychiatry : the journal of mental science, 2005, Volume: 187 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body W	2005
Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache, 2006, Volume: 46, Issue:5 Topics: Acute Disease; Adult; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Double-Blind Method; F	2006
Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of psychiatric practice, 2006, Volume: 12, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Double-Blind Meth	2006
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. Journal of psychiatric research, 2007, Volume: 41, Issue:8 Topics: Acute Disease; Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Comorbidity; F	2007
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology, 2006, Volume: 188, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents	2006
Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar disorders, 2006, Volume: 8, Issue:5 Pt 1 Topics: Acute Disease; Adult; Allopurinol; Antimanic Agents; Basal Ganglia Diseases; Bipolar Disorder; Doubl	2006
Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. The British journal of psychiatry : the journal of mental science, 2006, Volume: 189 Topics: Acute Disease; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Schizophrenia; Treatm	2006
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:10 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Sc	2006
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2 Topics: Acute Disease; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cholesterol; Diagnosti	2007
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of psychiatric practice, 2007, Volume: 13, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Do	2007
Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomised study. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 3 Topics: Acute Disease; Adolescent; Adult; Affect; Antipsychotic Agents; Diagnostic and Statistical Manual of	2009
Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Diseases of the nervous system, 1974, Volume: 35, Issue:3 Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Chlorpromazine; Dose-Response Rela	1974
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:11 Topics: Acute Disease; Adult; Algorithms; Antipsychotic Agents; Biomedical Research; Cooperative Behavior; D	2007
Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia. The British journal of psychiatry : the journal of mental science, 1984, Volume: 145 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trial	1984
Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens. Pharmacopsychiatria, 1983, Volume: 16, Issue:4 Topics: Acute Disease; Adult; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; F	1983
Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. The Journal of clinical psychiatry, 1984, Volume: 45, Issue:1 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Clinical Trials as Topic; Double-Blind Metho	1984
Droperidol vs. haloperidol in the initial management of acutely agitated patients. The Journal of clinical psychiatry, 1984, Volume: 45, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Clinical Trials as Topic; Commitment of Mentally Ill; Danger	1984
The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. Journal of psychiatric research, 1984, Volume: 18, Issue:3 Topics: Acute Disease; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Huma	1984
Antimanic effect of clonazepam. Biological psychiatry, 1983, Volume: 18, Issue:4 Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Benzodiazepinones; Bipolar Disorder; Clonazepa	1983
Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica, 1983, Volume: 3, Issue:5 Topics: Acute Disease; Adolescent; Adult; Aged; Anxiety Disorders; Bipolar Disorder; Female; Flupenthixol; H	1983
Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Behavioral considerations. Archives of general psychiatry, 1981, Volume: 38, Issue:2 Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Drug Administration Schedule; Haloperido	1981
Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria, 1982, Volume: 15, Issue:2 Topics: Acute Disease; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Ma	1982
Behavioral prediction of response to haloperidol: a test dose strategy. The Journal of clinical psychiatry, 1982, Volume: 43, Issue:4 Topics: Acute Disease; Dose-Response Relationship, Drug; Double-Blind Method; Haloperidol; Humans; Male; Par	1982
[Flupenthixol versus haloperidol in acute psychotic episodes]. Acta psychiatrica Belgica, 1982, Volume: 82, Issue:6 Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Double-Blind Method; Flupenthixol; Haloper	1982
A comparative study of parenteral molindone and haloperidol in the acutely psychotic patient. The Journal of clinical psychiatry, 1981, Volume: 42, Issue:5 Topics: Acute Disease; Adult; Crisis Intervention; Double-Blind Method; Female; Haloperidol; Humans; Indoles	1981
Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens. Archives of general psychiatry, 1980, Volume: 37, Issue:6 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Female; Ha	1980
Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication. Neuropsychobiology, 1995, Volume: 31, Issue:3 Topics: Acute Disease; Adult; Biogenic Monoamines; Female; Haloperidol; Humans; Hydrocortisone; Male; Prolac	1995
A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. Journal of clinical psychopharmacology, 1994, Volume: 14, Issue:6 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Arousal; Clopenthixol;	1994
A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta psychiatrica Scandinavica, 1993, Volume: 87, Issue:1 Topics: Acute Disease; Adult; Analysis of Variance; Antipsychotic Agents; Clopenthixol; Delayed-Action Prepa	1993
Positive versus negative symptoms in schizophrenia: response to haloperidol. Progress in neuro-psychopharmacology & biological psychiatry, 1994, Volume: 18, Issue:1 Topics: Acute Disease; Adult; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiatric Status Rat	1994
A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:4 Topics: Acute Disease; Administration, Oral; Adult; Basal Ganglia Diseases; Bipolar Disorder; Haloperidol; H	1996
Facial affect recognition in the course of schizophrenia. European archives of psychiatry and clinical neuroscience, 1996, Volume: 246, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; Emotions; Facia	1996
A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Acta psychiatrica Scandinavica, 1997, Volume: 95, Issue:4 Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; D	1997
Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biological psychiatry, 1997, Aug-15, Volume: 42, Issue:4 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Dibenzothiazepines; Dose-Response Rela	1997
Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta psychiatrica Scandinavica, 1998, Volume: 98, Issue:1 Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Bl	1998
Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. The American journal of psychiatry, 1999, Volume: 156, Issue:1 Topics: Acute Disease; Adult; Aggression; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind	1999
Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. Psychopharmacology, 1999, Volume: 141, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Female; Fenfluramine; Haloperidol; Humans; Male; Prolact	1999
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. The British journal of psychiatry : the journal of mental science, 1999, Volume: 174 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido	1999
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. International clinical psychopharmacology, 1999, Volume: 14, Issue:4 Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug	1999
Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:2 Topics: Acute Disease; Administration, Oral; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder	2000
Pretreatment plasma HVA and haloperidol response in acute mania. Journal of affective disorders, 2000, Volume: 59, Issue:1 Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug	2000
Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Comb	2000
No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. American journal of medical genetics, 2000, Jun-12, Volume: 96, Issue:3 Topics: Acute Disease; Alleles; Antipsychotic Agents; Benzamides; Dopamine Antagonists; Dopamine D2 Receptor	2000
Intravenous biperiden in akathisia: an open pilot study. International journal of psychiatry in medicine, 2000, Volume: 30, Issue:2 Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Biperiden; Cholinergic Antagoni	2000
Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:12 Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Administratio	2000
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-	2001
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2 Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric	2001
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:3 Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agent	2001
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. The American journal of psychiatry, 2001, Volume: 158, Issue:7 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship,	2001
Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania. Journal of child and adolescent psychopharmacology, 2001,Winter, Volume: 11, Issue:4 Topics: Acute Disease; Adolescent; Age Factors; Bipolar Disorder; Child; Double-Blind Method; Drug Therapy,	2001
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of general psychiatry, 2002, Volume: 59, Issue:5 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relatio	2002
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. The American journal of psychiatry, 2002, Volume: 159, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents	2002
A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Current therapeutic research, clinical and experimental, 1977, Volume: 21, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aggression; Brief Psychiatric Rating Scale; Clinical Trials as Top	1977
Hemispheric dysfunction in schizophrenia: assessment by visual perception tasks. Psychiatry research, 1979, Volume: 1, Issue:3 Topics: Acute Disease; Adult; Cerebral Cortex; Dominance, Cerebral; Double-Blind Method; Female; Haloperidol	1979
Droperidol in acutely agitated patients. A double-blind placebo-controlled study. The Journal of nervous and mental disease, 1977, Volume: 164, Issue:4 Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Droperidol; Drug	1977
Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study. Acta psychiatrica Scandinavica, 1977, Volume: 56, Issue:4 Topics: Acute Disease; Adult; Aged; Aggression; Biperiden; Clinical Trials as Topic; Dibenzoxazepines; Doubl	1977
Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Diseases of the nervous system, 1977, Volume: 38, Issue:12 Topics: Acute Disease; Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation	1977
A comparison of the efficacy and acceptability of two formulations of injectable serenace in the treatment of states of excitement. The Journal of international medical research, 1978, Volume: 6, Issue:3 Topics: Acute Disease; Adult; Chemistry, Pharmaceutical; Clinical Trials as Topic; Double-Blind Method; Fema	1978
Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol. The American journal of psychiatry, 1979, Volume: 136, Issue:3 Topics: Acute Disease; Administration, Oral; Basal Ganglia Diseases; Bipolar Disorder; Clinical Trials as To	1979
Acute high-dose parenteral haloperidol treatment of psychosis. The American journal of psychiatry, 1979, Volume: 136, Issue:8 Topics: Acute Disease; Adult; Bipolar Disorder; Blood Pressure; Clinical Trials as Topic; Diazepam; Dose-Res	1979
A controlled double-blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients. Psychopharmacology bulletin, 1976, Volume: 12, Issue:2 Topics: Acute Disease; Clinical Trials as Topic; Dibenzoxazepines; Haloperidol; Humans; Loxapine; Schizophre	1976
Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics. Current therapeutic research, clinical and experimental, 1976, Volume: 19, Issue:6 Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Dibenzoxazepines; Female; Haloperidol; H	1976
Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol. Current therapeutic research, clinical and experimental, 1976, Volume: 20, Issue:5 Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Female; Fluphenazine; Haloperidol; Human	1976
Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited. Archives of general psychiatry, 1992, Volume: 49, Issue:12 Topics: Acute Disease; Haloperidol; Homovanillic Acid; Humans; Placebos; Psychiatric Status Rating Scales; S	1992
Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. Pharmacopsychiatry, 1992, Volume: 25, Issue:6 Topics: Acute Disease; Adult; Drug Therapy, Combination; Female; Haloperidol; Humans; Lorazepam; Male; Middl	1992
[Disagreement in standardized haloperidol treatment in comparison with "adequate individual dosage" of acutely schizophrenic patients]. Fortschritte der Neurologie-Psychiatrie, 1992, Volume: 60, Issue:3 Topics: Acute Disease; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Hu	1992
Haloperidol blood levels and clinical effects. Archives of general psychiatry, 1992, Volume: 49, Issue:5 Topics: Acute Disease; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Placebos; Psy	1992
Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. The Journal of clinical psychiatry, 1991, Volume: 52, Issue:4 Topics: Acute Disease; Adult; Aggression; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combinati	1991
[Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients]. Fortschritte der Neurologie-Psychiatrie, 1991, Volume: 59 Suppl 1 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Dibenzothiepins; Dose-Response Relationship,	1991
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of general psychiatry, 1991, Volume: 48, Issue:8 Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Double-Blind Method; Drug Administration S	1991
Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacology bulletin, 1991, Volume: 27, Issue:2 Topics: Acute Disease; Haloperidol; Humans; Prognosis; Psychiatric Status Rating Scales; Schizophrenia; Schi	1991
Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol. Psychopharmacology bulletin, 1990, Volume: 26, Issue:1 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Double-Blind Method; Female; Hal	1990
Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacology, 1990, Volume: 102, Issue:1 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Delayed-Action Preparations; Dou	1990
A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia. Acta psychiatrica Scandinavica. Supplementum, 1990, Volume: 358 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Double-Blind Method; Female; Hal	1990
Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. Acta psychiatrica Scandinavica. Supplementum, 1990, Volume: 358 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship	1990
A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Acta psychiatrica Scandinavica. Supplementum, 1990, Volume: 358 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship	1990
A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. Acta psychiatrica Scandinavica. Supplementum, 1990, Volume: 358 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Dose-Response Relationship, Drug	1990
A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia. Acta psychiatrica Scandinavica. Supplementum, 1990, Volume: 358 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; De	1990
A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Acta psychiatrica Scandinavica. Supplementum, 1990, Volume: 358 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Canada; Dose-Response Relationsh	1990
Dosage of haloperidol for schizophrenia. Archives of general psychiatry, 1991, Volume: 48, Issue:2 Topics: Acute Disease; Administration, Oral; Adult; Drug Administration Schedule; Female; Haloperidol; Hospi	1991
Comparison of sensorimotor and cognitive performance of acute schizophrenic inpatients treated with remoxipride or haloperidol. Neuropsychobiology, 1989, Volume: 21, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzamides; Cognition; Double-Blind Method; Female; Halo	1989
Carbamazepine compared to haloperidol in acute mania. International clinical psychopharmacology, 1989, Volume: 4, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Bipolar Disorder; Carbamazepine; Chlor	1989
Navane versus Haldol. Treatment of acute organic mental syndromes in the general hospital. General hospital psychiatry, 1989, Volume: 11, Issue:6 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Female; Haloperidol; Humans; Male; Middle Aged; Neuro	1989
Rapid tranquilization: the efficacy of oral concentrate. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:11 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Drug Administrat	1985
The use of benzodiazepines in the treatment of manic-depressive illness. The Journal of clinical psychiatry, 1988, Volume: 49 Suppl Topics: Acute Disease; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Basal Ga	1988
Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry, 1988, Volume: 21, Issue:5 Topics: Acute Disease; Adult; Female; Haloperidol; Humans; Male; Prognosis; Prolactin; Psychiatric Status Ra	1988
Clonazepam in acute and maintenance treatment of bipolar affective disorder. The Journal of clinical psychiatry, 1987, Volume: 48 Suppl Topics: Acute Disease; Adult; Bipolar Disorder; Clinical Trials as Topic; Clonazepam; Double-Blind Method; D	1987
Experimental comparison of the effectivity of individually adapted and standardized dosages of haloperidol. Neuropsychobiology, 1987, Volume: 18, Issue:3 Topics: Acute Disease; Adult; Double-Blind Method; Haloperidol; Humans; Middle Aged; Psychiatric Status Rati	1987
A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. The Journal of clinical psychiatry, 1986, Volume: 47, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aggression; Clinical Trials as Topic;	1986
Utility of neuroleptic blood levels in the treatment of acute psychosis. The Journal of clinical psychiatry, 1986, Volume: 47, Issue:12 Topics: Acute Disease; Adult; Female; Haloperidol; Humans; Male; Outcome and Process Assessment, Health Care	1986
Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:8 Pt 2 Topics: Acute Disease; Administration, Oral; Adult; Clinical Trials as Topic; Double-Blind Method; Female; H	1985
Comparison of injectable haloperidol and chlorpromazine. The American journal of psychiatry, 1972, Volume: 129, Issue:1 Topics: Acute Disease; Adult; Age Factors; Aged; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as	1972
Sleeplessness in acute and chronic schizophrenia--response to haloperidol and anti-parkinsonism agents. Psychopharmacologia, 1973, Feb-27, Volume: 29, Issue:1 Topics: Acute Disease; Adult; Antiparkinson Agents; Arousal; Benztropine; Chronic Disease; Clinical Trials a	1973
Psychopharmacological study of schizophrenia--some ways out of an impasse. A case study with haloperidol. International pharmacopsychiatry, 1973, Volume: 8, Issue:1 Topics: Acute Disease; Benztropine; Clinical Trials as Topic; Cognition Disorders; Dose-Response Relationshi	1973
Penfluridol: an efficacious long-acting oral antipsychotic compound. The American journal of psychiatry, 1974, Volume: 131, Issue:6 Topics: Acute Disease; Administration, Oral; Chromatography, Gas; Clinical Trials as Topic; Cooperative Beha	1974
The current status of lithium in psychiatry. The American journal of the medical sciences, 1974, Volume: 268, Issue:6 Topics: Acute Disease; Bipolar Disorder; Chlorpromazine; Clinical Trials as Topic; Depression; Female; Halop	1974
Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action. International journal of neuropsychiatry, 1967, Volume: 3 Topics: Acute Disease; Antidepressive Agents; Chlorpromazine; Clinical Trials as Topic; Haloperidol; Humans;	1967
Treatment of acute exacerbations in chronic schizophrenic patients. International journal of neuropsychiatry, 1967, Volume: 3 Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middl	1967
Haloperidol for acute psychiatric emergencies: a double-blind comparison with perphenazine in acute alcoholic psychosis. Southern medical journal, 1971, Volume: 64, Issue:2 Topics: Acute Disease; Adult; Aged; Clinical Trials as Topic; Haloperidol; Humans; Male; Middle Aged; Perphe	1971
A comparison of chlorprothixene and haloperidol in acute schizophrenia. Canadian Psychiatric Association journal, 1971, Volume: 16, Issue:6 Topics: Acute Disease; Adolescent; Adult; Chlorprothixene; Clinical Trials as Topic; Electroencephalography;	1971
Treatment of acute and chronic psychoses with haloperidol: review of clinical results. Current therapeutic research, clinical and experimental, 1969, Volume: 11, Issue:5 Topics: Acute Disease; Chlorpromazine; Chlorprothixene; Chronic Disease; Haloperidol; Humans; Schizophrenia	1969
A double-blind comparison of haloperidol with perphenazine in acute psychiatric episodes. Current therapeutic research, clinical and experimental, 1969, Volume: 11, Issue:8 Topics: Acute Disease; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Female; Haloperidol; Humans; M	1969
A controlled evaluation of haloperidol, chlorpromazine, and sodium amobarbital: intramuscular short-term use in acute psychotic patients. Current therapeutic research, clinical and experimental, 1969, Volume: 11, Issue:9 Topics: Acute Disease; Adult; Amobarbital; Chlorpromazine; Clinical Trials as Topic; Female; Haloperidol; Hu	1969
Changes in cognition, attention and language in acute schizophrenia. Diseases of the nervous system, 1969, Volume: 30, Issue:1 Topics: Acute Disease; Adolescent; Adult; Attention; Cognition; Female; Haloperidol; Humans; Intelligence Te	1969

Article	Year
Acute Onset Psychosis With Mystical Delusions in a Young Male Patient Following Discontinuation of Corticosteroid Therapy: A Case Report. Journal of psychiatric practice, 2022, 09-01, Volume: 28, Issue:5 Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Delusions; Haloperidol; Humans; Male; Psychotic D	2022
Is acute dystonia an emergency? Sometimes, it really is! Pediatric emergency care, 2013, Volume: 29, Issue:3 Topics: Acute Disease; Adolescent; Antipsychotic Agents; Biperiden; Chlorpromazine; Diagnosis, Differential;	2013
The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:5 Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Catechol O-Methyltransferase; Ch	2013
Treatment of acute migraine in the emergency department. Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:1 Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents	2014
Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism. Neuropharmacology, 2015, Volume: 95 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Catalepsy; Corpus Striatum; En	2015
[Three cases of acute serotonin syndrome due to psilocybin mushroom poisoning]. Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology, 2016, Volume: 29, Issue:1 Topics: Acute Disease; Adult; Agaricales; Aged; Charcoal; Diazepam; Female; Fluid Therapy; Haloperidol; Huma	2016
Case of acute psychosis from herbal supplements. South Dakota medicine : the journal of the South Dakota State Medical Association, 2008, Volume: 61, Issue:5 Topics: Acute Disease; Adult; Antipsychotic Agents; Dietary Supplements; Female; Haloperidol; Humans; Loraze	2008
Acute disseminated encephalomyelitis presenting as acute psychotic disorder. Indian pediatrics, 2008, Volume: 45, Issue:12 Topics: Acute Disease; Anti-Inflammatory Agents; Antipsychotic Agents; Child; Child, Preschool; Diagnosis, D	2008
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:1 Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaze	2009
[Depression in schizophrenia]. Vestnik Rossiiskoi akademii meditsinskikh nauk, 2008, Issue:10 Topics: Acute Disease; Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Chi-S	2008
Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study. Pharmacotherapy, 2009, Volume: 29, Issue:8 Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Cholinergic Antago	2009
Paradoxical vocal cord motion--haloperidol usage in acute attack treatment. The Journal of craniofacial surgery, 2009, Volume: 20, Issue:5 Topics: Acute Disease; Adolescent; Antipsychotic Agents; Botulinum Toxins, Type A; Dyspnea; Haloperidol; Hum	2009
Acute altered mental status in a psychiatric patient. The Journal of the Arkansas Medical Society, 2009, Volume: 106, Issue:5 Topics: Acute Disease; Adult; Antipsychotic Agents; Benztropine; Consciousness Disorders; Diagnosis, Differe	2009
[Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up]. L'Encephale, 2010, Volume: 36, Issue:1 Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Cataplexy; C	2010
[Acutely confused old man]. MMW Fortschritte der Medizin, 2010, Feb-11, Volume: 152, Issue:6 Topics: Acute Disease; Aged; Antipsychotic Agents; Benzodiazepines; Butyrophenones; Confusion; Haloperidol;	2010
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3. Rapid tranquilisation in acute psychotic agitation. Emergency medicine journal : EMJ, 2011, Volume: 28, Issue:1 Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Emergencies; Emergency Medicine; Emergency Ser	2011
[Acute psychotic access following the administration of isoniazid]. Revue de pneumologie clinique, 2011, Volume: 67, Issue:2 Topics: Acute Disease; Antipsychotic Agents; Antitubercular Agents; Chlorpromazine; Diagnosis, Differential;	2011
A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. The Journal of emergency medicine, 2012, Volume: 43, Issue:5 Topics: Acute Disease; Adult; Alcoholic Intoxication; Analysis of Variance; Antipsychotic Agents; Benzodiaze	2012
A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug	2012
Delayed and severe but transient Tourette syndrome after head injury. Pediatric neurology, 2002, Volume: 27, Issue:4 Topics: Acute Disease; Child; Craniocerebral Trauma; Female; Haloperidol; Humans; Tourette Syndrome	2002
Cerebral metabolic patterns in chronic and recent-onset schizophrenia. Psychiatry research, 2003, Feb-15, Volume: 122, Issue:2 Topics: Acute Disease; Adult; Basal Ganglia; Brain; Brain Mapping; Cerebellum; Cerebral Cortex; Chronic Dise	2003
[Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients]. MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2 Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical T	2003
[Acute dystonia due to haloperidol during labor]. Revista espanola de anestesiologia y reanimacion, 2004, Volume: 51, Issue:4 Topics: Acute Disease; Adult; Dystonia; Female; Haloperidol; Humans; Obstetric Labor Complications; Pregnanc	2004
Beyond haloperidol: teaching emergency medicine residents to manage acute agitation and aggression in the emergency department. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2004, Volume: 49, Issue:8 Topics: Acute Disease; Aggression; Antipsychotic Agents; Emergency Medical Services; Emergency Medicine; Hal	2004
Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol. The Journal of the Association of Physicians of India, 2004, Volume: 52 Topics: Acute Disease; Adult; Antimanic Agents; Bipolar Disorder; Chlorpromazine; Diabetic Ketoacidosis; Dia	2004
Suicide risk in placebo-controlled trials of treatment for acute manic episode and prevention of manic-depressive episode. The American journal of psychiatry, 2005, Volume: 162, Issue:4 Topics: Acute Disease; Antipsychotic Agents; Bipolar Disorder; Clinical Trials Data Monitoring Committees; D	2005
Acute brain syndrome as a consequence of the Cronkhite-Canada syndrome. Psychiatria Danubina, 2005, Volume: 17, Issue:1-2 Topics: Acute Disease; Aged; Dementia; Drug Therapy, Combination; Female; Haloperidol; Humans; Intestinal Po	2005
[Some peculiarities of clinical signs and treatment of alcoholic psychosis in women]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2006, Volume: 106, Issue:3 Topics: Acute Disease; Adult; Age Factors; Anti-Anxiety Agents; Antipsychotic Agents; Diazepam; Drug Therapy	2006
Psychosis and Wilson's disease: a case report. Psychiatria Danubina, 2006, Volume: 18, Issue:1-2 Topics: Acute Disease; Adult; Antipsychotic Agents; Athetosis; Chelating Agents; Chorea; Diagnosis, Differen	2006
Possible antipsychotic effects of minocycline in patients with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Jan-30, Volume: 31, Issue:1 Topics: Acute Disease; Adult; Anti-Bacterial Agents; Antipsychotic Agents; Electroencephalography; Haloperid	2007
Hemichorea associated with polycythaemia vera. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2006, Volume: 27, Issue:6 Topics: Acute Disease; Aged; Anti-Dyskinesia Agents; Chorea; Dopamine Antagonists; Female; Haloperidol; Huma	2006
Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient. Archives of gerontology and geriatrics, 2007, Volume: 44 Suppl 1 Topics: Acute Disease; Aged, 80 and over; Alzheimer Disease; Amitriptyline; Antipsychotic Agents; Cholinergi	2007
[Acute psychosis: in an emergency always still haloperidol?]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:3 Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Emergencies; Haloperidol; Humans; Injecti	2008
[Postictal paranoid-hallucinatory psychosis in cryptogenic epilepsy]. Psychiatrische Praxis, 2007, Volume: 34, Issue:5 Topics: Acute Disease; Adult; Anticonvulsants; Cooperative Behavior; Delusions; Diazepam; Epilepsy; Epilepsy	2007
Three cases of schizophrenia for which olanzapine was effective after early acute phase. Psychiatry and clinical neurosciences, 2008, Volume: 62, Issue:1 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Foll	2008
[Acute extrapyramidal syndrome and neuroleptical malignant syndrome. A case report]. Recenti progressi in medicina, 2008, Volume: 99, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Haloperidol; Humans; Injections,	2008
Clinical efficacy of haloperidol in chronic psychotic patients. International journal of neuropsychiatry, 1967, Volume: 3 Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Female; Haloperidol; Humans; Male; Middle A	1967
Hypothyroidism, psychotropic drugs and cardiotoxicity. The British journal of psychiatry : the journal of mental science, 1980, Volume: 136 Topics: Acute Disease; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Hypothyroidism; Phenothiazi	1980
Acute dystonia as idiosyncratic reaction to haloperidol. Lancet (London, England), 1980, Aug-30, Volume: 2, Issue:8192 Topics: Acute Disease; Child; Dystonia; Female; Haloperidol; Humans; Hypertension	1980
[Neuroleptic large dose therapy of schizophrenias]. Psychiatrie, Neurologie, und medizinische Psychologie, 1981, Volume: 33, Issue:4 Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combinat	1981
Neuroleptic-induced acute dyskinesias in rhesus monkeys. Psychopharmacology, 1981, Volume: 75, Issue:1 Topics: Acute Disease; Animals; Antipsychotic Agents; Benzamides; Disease Models, Animal; Dyskinesia, Drug-I	1981
[Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients]. Der Nervenarzt, 1982, Volume: 53, Issue:9 Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; H	1982
Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings. Psychopharmacology bulletin, 1983, Volume: 19, Issue:1 Topics: Acute Disease; Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Radioligand Assa	1983
Therapeutic window for plasma haloperidol in acute schizophrenic psychosis. Lancet (London, England), 1983, May-07, Volume: 1, Issue:8332 Topics: Acute Disease; Adult; Female; Haloperidol; Humans; Schizophrenia, Paranoid	1983
Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys. Psychopharmacology, 1984, Volume: 82, Issue:1-2 Topics: Acute Disease; alpha-Methyltyrosine; Animals; Avoidance Learning; Catecholamines; Dyskinesia, Drug-I	1984
Lack of tolerance to haloperidol-induced acute dyskinesias in rhesus monkeys. Psychopharmacology, 1984, Volume: 82, Issue:1-2 Topics: Acute Disease; Animals; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Macaca mulatta	1984
[Treatment of several psychotic states with the combination of valproic acid with diazepam]. Annales medico-psychologiques, 1984, Volume: 142, Issue:9 Topics: Acute Disease; Adult; Delusions; Diazepam; Drug Therapy, Combination; Female; Hallucinations; Halope	1984
Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis. The American journal of psychiatry, 1984, Volume: 141, Issue:10 Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychia	1984
Differential drug effects identified by 3-way configural frequency analysis. Neuropsychobiology, 1984, Volume: 11, Issue:4 Topics: Acute Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Prognosis; Schizophrenia; Schi	1984
An unusual schizophrenic illness responsive to pyridoxine HCl (B6) subsequent to phenothiazine and butyrophenone toxicities. Biological psychiatry, 1983, Volume: 18, Issue:11 Topics: Acute Disease; Adolescent; Basal Ganglia Diseases; Drug Administration Schedule; Follow-Up Studies;	1983
Disturbances of thirst and water homeostasis in patients with affective illness. The American journal of psychiatry, 1984, Volume: 141, Issue:3 Topics: Acute Disease; Adult; Aged; Bipolar Disorder; Drinking Behavior; Female; Haloperidol; Humans; Hypona	1984
Plasma catecholamine metabolites and early response to haloperidol. The Journal of clinical psychiatry, 1984, Volume: 45, Issue:6 Topics: Acute Disease; Adolescent; Adult; Female; Glycols; Haloperidol; Homovanillic Acid; Hospitalization;	1984
Plasma level and effect of low-dose haloperidol in acute psychosis. Psychopharmacology bulletin, 1984,Spring, Volume: 20, Issue:2 Topics: Acute Disease; Administration, Oral; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Psychoti	1984
Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. The Journal of clinical psychiatry, 1984, Volume: 45, Issue:8 Topics: Acute Disease; Adult; Dystonia; Haloperidol; Humans; Male; Muscles; Myoglobinuria; Psychotic Disorde	1984
Sex differences in plasma homovanillic acid in acute psychosis. The New England journal of medicine, 1983, Apr-07, Volume: 308, Issue:14 Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged;	1983
Physostigmine and haloperidol treatment of acute phencyclidine intoxication. The American journal of psychiatry, 1982, Volume: 139, Issue:4 Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Humans; Male; Phencyclidine Abuse; Physostigm	1982
Rapid tranquilization. Hospital & community psychiatry, 1982, Volume: 33, Issue:5 Topics: Acute Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Psychotic Disorders	1982
Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacology bulletin, 1982, Volume: 18, Issue:4 Topics: Acute Disease; Adult; Haloperidol; Humans; Schizophrenia	1982
[Depressive states in schizophrenic in-patients on admission and at discharge (author's transl)]. Der Nervenarzt, 1981, Volume: 52, Issue:9 Topics: Acute Disease; Depressive Disorder; Haloperidol; Hospitals, Psychiatric; Humans; Motivation; Schizop	1981
[The acute psychiatric emergency]. Zeitschrift fur Alternsforschung, 1981, Volume: 36, Issue:4 Topics: Acute Disease; Aged; Alcoholism; Amitriptyline; Brain Ischemia; Cognition Disorders; Consciousness D	1981
Relationship of serum haloperidol levels to clinical response in schizophrenic patients. The American journal of psychiatry, 1981, Volume: 138, Issue:3 Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status	1981
Distractibility in schizophrenia. Psychiatry research, 1995, Jul-28, Volume: 57, Issue:2 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Attention; Chronic Disease; Cognition Disord	1995
Safe use of haloperidol in acute intermittent porphyria. The Annals of pharmacotherapy, 1995, Volume: 29, Issue:2 Topics: Acute Disease; Adult; Confusion; Hallucinations; Haloperidol; Humans; Male; Porphyria, Acute Intermi	1995
The relationship between motor effects in rats following acute and chronic haloperidol treatment. Psychopharmacology, 1994, Volume: 116, Issue:1 Topics: Acute Disease; Animals; Catalepsy; Chronic Disease; Disease Models, Animal; Dyskinesia, Drug-Induced	1994
Neuroleptic prescriptions for acutely ill geriatric patients. Archives of internal medicine, 1993, Nov-22, Volume: 153, Issue:22 Topics: Acute Disease; Aged; Aged, 80 and over; Antipsychotic Agents; Drug Utilization; Female; Haloperidol;	1993
Acute accidental overdosage of haloperidol in children. Acta paediatrica (Oslo, Norway : 1992), 1993, Volume: 82, Issue:10 Topics: Acute Disease; Child; Child, Preschool; Drug Contamination; Drug Overdose; Female; Haloperidol; Huma	1993
Acute dystonia due to clozapine. Journal of neurology, neurosurgery, and psychiatry, 1994, Volume: 57, Issue:1 Topics: Acute Disease; Biperiden; Clozapine; Dystonia; Haloperidol; Humans; Male; Middle Aged; Schizophrenia	1994
Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state. The Japanese journal of psychiatry and neurology, 1993, Volume: 47, Issue:3 Topics: Acute Disease; Adolescent; Adult; Cross-Cultural Comparison; Dose-Response Relationship, Drug; Femal	1993
Acutely psychotic patients receiving high-dose haloperidol therapy. Journal of clinical psychopharmacology, 1993, Volume: 13, Issue:1 Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Crisis Intervention; Dose-Response Relationship,	1993
Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychological medicine, 1996, Volume: 26, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Catatonia; Combined Modality Therapy; Creatine Kinase; D	1996
[Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation]. L'Encephale, 1996, Volume: 22 Spec No 3 Topics: Acute Disease; Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Prognosis; Prolactin; Psychia	1996
[Acute recurrent dystonia secondary to neuroleptic suppression]. Revista clinica espanola, 1997, Volume: 197, Issue:3 Topics: Acute Disease; Antipsychotic Agents; Dystonia; Haloperidol; Humans; Male; Middle Aged; Recurrence; S	1997
[Acute encephalomyopathy and persistent cerebellar syndrome after lithium salt and haloperidol poisoning]. Revue neurologique, 1997, Volume: 153, Issue:4 Topics: Acute Disease; Adult; Antidepressive Agents; Antipsychotic Agents; Brain Diseases; Cerebellar Diseas	1997
The common marmoset (Callithrix jacchus) as a model for neuroleptic-induced acute dystonia. Pharmacology, biochemistry, and behavior, 1997, Volume: 58, Issue:4 Topics: Acute Disease; Animals; Antipsychotic Agents; Callithrix; Cholinergic Antagonists; Dose-Response Rel	1997
Possible pitfalls in the diagnosis of acute myocardial infarction in acutely psychotic patients. The Israel journal of psychiatry and related sciences, 1997, Volume: 34, Issue:4 Topics: Acute Disease; Adult; Creatine Kinase; Diagnostic Errors; Electrocardiography; Emergency Service, Ho	1997
Neuroleptic-induced laryngeal dystonia can mimic anaphylaxis. The Australian and New Zealand journal of psychiatry, 1997, Volume: 31, Issue:6 Topics: Acute Disease; Adult; Anaphylaxis; Antipsychotic Agents; Diagnosis, Differential; Dystonia; Haloperi	1997
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Critical care medicine, 1998, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response	1998
Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophrenia research, 1998, May-04, Volume: 31, Issue:1 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzamides; Brain; Dopamine Antagonists; Haloperidol; Hu	1998
Acute laryngeal dystonia related to neuroleptic agents. The American journal of emergency medicine, 1999, Volume: 17, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Diphenhydramine; Dystonia; Female; Halo	1999
Mania onset while using dehydroepiandrosterone. The American journal of psychiatry, 1999, Volume: 156, Issue:6 Topics: Acute Disease; Bipolar Disorder; Dehydroepiandrosterone; Drug Therapy, Combination; Haloperidol; Hum	1999
A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep. Psychiatry and clinical neurosciences, 1999, Volume: 53, Issue:2 Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dominance, Cerebral; Dose-Respo	1999
Emergency psychiatry: contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatric services (Washington, D.C.), 1999, Volume: 50, Issue:12 Topics: Acute Disease; Antipsychotic Agents; Drug Administration Schedule; Emergency Services, Psychiatric;	1999
Non-ketotic hyperglycemia in a young woman, presenting as hemiballism-hemichorea. Acta neurologica Scandinavica, 1999, Volume: 100, Issue:6 Topics: Acute Disease; Adult; Anti-Dyskinesia Agents; Brain; Chorea; Diagnosis, Differential; Dyskinesias; F	1999
Current antipsychotic dose correlates to mononuclear cell counts in the cerebrospinal fluid of psychotic patients. Psychiatry research, 2000, Feb-14, Volume: 93, Issue:1 Topics: Acute Disease; Adult; Angiotensin I; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies;	2000
["More is less": a retrospective study of haloperidol dosages in acute schizophrenia]. Psychiatrische Praxis, 2000, Volume: 27, Issue:2 Topics: Acute Disease; Anti-Anxiety Agents; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Dos	2000
Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. American journal of medical genetics, 2000, Apr-03, Volume: 96, Issue:2 Topics: Acute Disease; Akathisia, Drug-Induced; Amino Acid Substitution; Antipsychotic Agents; Dyskinesias;	2000
[Mental disorders in acute neuroleptic poisoning]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1999, Volume: 99, Issue:8 Topics: Acute Disease; Adult; Age Distribution; Antipsychotic Agents; Chlorpromazine; Clozapine; Female; Hal	1999
Management of acute psychosis. The Australian and New Zealand journal of psychiatry, 2000, Volume: 34, Issue:5 Topics: Acute Disease; Anti-Anxiety Agents; Antipsychotic Agents; Australia; Benzodiazepines; Contraindicati	2000
Neurosyphilis presenting as schizophrenialike psychosis. Neuropsychiatry, neuropsychology, and behavioral neurology, 2000, Volume: 13, Issue:4 Topics: Acute Disease; Adult; Diagnosis, Differential; Female; Frontal Lobe; Haloperidol; Humans; Neurosyphi	2000
Acute phase of schizophrenia: impact of atypical antipsychotics. International clinical psychopharmacology, 2000, Volume: 15 Suppl 4 Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Haloperidol; Humans; Prognosis; Recurrence; Risper	2000
Haloperidol and benztropine interaction presenting as acute intestinal pseudo-obstruction. The American journal of gastroenterology, 2001, Volume: 96, Issue:3 Topics: Acute Disease; Aged; Antipsychotic Agents; Benztropine; Drug Interactions; Female; Haloperidol; Huma	2001
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic. The American journal of psychiatry, 2001, Volume: 158, Issue:4 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Emergency Se	2001
The changes of biological markers and treatment efficacy in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 2001, Volume: 25, Issue:2 Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Biomarkers; Brain; Cognition; Dexamethasone	2001
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:3 Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Emergen	2001
Association between severity of schizophrenic symptoms and urinary retention. European psychiatry : the journal of the Association of European Psychiatrists, 2001, Volume: 16, Issue:8 Topics: Acute Disease; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Remission Induction; Schizo	2001
Letter: Dosage for antipsychotic drugs (concl.). The New England journal of medicine, 1976, 07-15, Volume: 295, Issue:3 Topics: Acute Disease; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders	1976
The effects of haloperidol, chlorpromazine and propranolol on acute amphetamine poisoning in the conscious dog. The Journal of pharmacology and experimental therapeutics, 1977, Volume: 202, Issue:1 Topics: Acute Disease; Animals; Aspartate Aminotransferases; Blood Glucose; Blood Pressure; Body Temperature	1977
Acutely disturbed psychotic patients treated with parenteral haloperidol. IMJ. Illinois medical journal, 1978, Volume: 153, Issue:2 Topics: Acute Disease; Adult; Aged; Female; Haloperidol; Humans; Infusions, Parenteral; Male; Middle Aged; P	1978
The treatment of severely depressed schizophrenic patients. American journal of psychotherapy, 1978, Volume: 32, Issue:1 Topics: Acute Disease; Antipsychotic Agents; Delayed-Action Preparations; Depression; Electroconvulsive Ther	1978
Urinary incontinence in patients receiving neuroleptics. The Journal of clinical psychiatry, 1979, Volume: 40, Issue:6 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Brain; Chlorpromazine; Female; Fluphenazine;	1979
[Effective management of the acute psychotic patient: stabilization and maintenance with haloperidol]. Acta psiquiatrica y psicologica de America latina, 1978, Volume: 24, Issue:4 Topics: Acute Disease; Antipsychotic Agents; Drug Administration Schedule; Haloperidol; Hospitalization; Hum	1978
Use of oral haloperidol following rapid tranquilization of acutely disturbed patients. The West Virginia medical journal, 1978, Volume: 74, Issue:3 Topics: Acute Disease; Administration, Oral; Haloperidol; Humans; Psychotic Disorders	1978
[Rapid control of the acute patient by haloperidol administration]. Acta psiquiatrica y psicologica de America latina, 1979, Volume: 25, Issue:3 Topics: Acute Disease; England; Haloperidol; History, 20th Century; Humans; Hyperkinesis; Injections, Intram	1979
Acute dystonia as an idiosyncratic response to neuroleptics in baboons. Brain : a journal of neurology, 1977, Volume: 100, Issue:2 Topics: 5-Hydroxytryptophan; Acute Disease; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; H	1977
Prevention of protein extravasation in the brain by an anion transport inhibitor in acute experimental hypertension in rats. Acta physiologica Scandinavica, 1979, Volume: 105, Issue:4 Topics: Acute Disease; Animals; Anions; Bicuculline; Blood Proteins; Blood-Brain Barrier; Cerebrospinal Flui	1979
Hypertension in acute haloperidol poisoning. The Journal of pediatrics, 1979, Volume: 95, Issue:3 Topics: Acute Disease; Female; Haloperidol; Humans; Hypertension; Infant	1979
Toxic reactions from a haloperidol overdose in two children. Thermal and cardiac manifestations. JAMA, 1978, Jan-02, Volume: 239, Issue:1 Topics: Accidents, Home; Acute Disease; Age Factors; Bradycardia; Child, Preschool; Female; Fever; Haloperid	1978
Acute haloperidol poisoning in children. The Journal of pediatrics, 1978, Volume: 93, Issue:6 Topics: Acute Disease; Antiparkinson Agents; Basal Ganglia Diseases; Biperiden; Child; Child, Preschool; Dys	1978
Questions about rapid treatment. The American journal of psychiatry, 1977, Volume: 134, Issue:5 Topics: Acute Disease; Bipolar Disorder; Emergency Service, Hospital; Female; Haloperidol; Humans; Psychotic	1977
Psychotolysis with haloperidol. Rapid control of the acutely disturbed psychotic patient. Diseases of the nervous system, 1977, Volume: 38, Issue:4 Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Conflict, Psychological; Female; Hallucina	1977
Concomitant administration of haloperidol and lithium carbonate in acute mania. Diseases of the nervous system, 1977, Volume: 38, Issue:9 Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Drug Therapy, Combination; Haloperidol; Humans;	1977
[Acute dystonic reaction due to haloperidol]. Harefuah, 1977, Volume: 93, Issue:3-4 Topics: Acute Disease; Child; Haloperidol; Humans; Muscular Diseases	1977
Rapid treatment of acute psychosis. The American journal of psychiatry, 1976, Volume: 133, Issue:9 Topics: Acute Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Psychotic Disorders; Time Fact	1976
[Ambulatory treatment of psychoses. Report from a discussion meeting]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1976, Aug-30, Volume: 96, Issue:24 Topics: Acute Disease; Administration, Oral; Ambulatory Care; Depression; Haloperidol; Humans; Injections, I	1976
Treatment and prognosis of hemiballismus. The New England journal of medicine, 1976, Dec-09, Volume: 295, Issue:24 Topics: Acute Disease; Aged; Chlorpromazine; Diencephalon; Dopamine; Feedback; Female; Haloperidol; Homovani	1976
The rapid control of the acute patient by haloperidol. Proceedings of the Royal Society of Medicine, 1976, Volume: 69 suppl 1 Topics: Acute Disease; Age Factors; Body Weight; Female; Haloperidol; Humans; Male; Mental Disorders; Sex Fa	1976
Efficient management of the acute psychotic patient: stabilization and maintenance with haloperidol. Proceedings of the Royal Society of Medicine, 1976, Volume: 69 suppl 1 Topics: Acute Disease; Half-Life; Haloperidol; Humans; Psychotic Disorders	1976
Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Archives of general psychiatry, 1975, Volume: 32, Issue:3 Topics: Acute Disease; Adult; Amitriptyline; Benztropine; Chemical Phenomena; Chemistry; Cholinesterase Inhi	1975
Technique of fluphenazine decanoate therapy in acute schizophrenic illnesses. Diseases of the nervous system, 1975, Volume: 36, Issue:10 Topics: Acute Disease; Ambulatory Care; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluphen	1975
Letter: Haloperidol for acute amphetamine poisoning: a study in dogs. JAMA, 1975, Mar-31, Volume: 231, Issue:13 Topics: Acute Disease; Amphetamine; Animals; Dogs; Haloperidol; Injections, Intravenous	1975
[The use of the brief psychiatric rating scale (BPRS) by overall and gorham for the diagnosis of acute paranoid psychoses: evaluation of a german translation of the BPRS (author's transl)]. Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1975, Volume: 8, Issue:5 Topics: Acute Disease; Germany, West; Haloperidol; Humans; Loxapine; Schizophrenia, Paranoid	1975
Acutely administered haloperidol-induced pattern changes of regional cerebral blood flow in schizophrenics. Observation from subtraction of brain imaging with single photon emission computed tomography using technetium-99m hexamethyl-propyleneamine oxime. Neuropsychobiology, 1992, Volume: 25, Issue:4 Topics: Acute Disease; Adult; Brain; Cerebral Cortex; Dose-Response Relationship, Drug; Female; Haloperidol;	1992
You drive me crazy: a case report of acute psychosis and neurocysticercosis. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1992, Volume: 37, Issue:2 Topics: Acute Disease; Adult; Brain Diseases; Cysticercosis; Dexamethasone; Electroencephalography; Female;	1992
The antiinflammatory effect of dopamine in alcoholic hemorrhagic pancreatitis in cats. Studies on the receptors and mechanisms of action. Gastroenterology, 1991, Volume: 101, Issue:6 Topics: Acute Disease; Alcoholism; Animals; Capillary Permeability; Cats; Dopamine; Ethanol; Haloperidol; He	1991
Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited. Archives of general psychiatry, 1990, Volume: 47, Issue:2 Topics: Acute Disease; Adult; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methox	1990
Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. The Journal of clinical psychiatry, 1991, Volume: 52, Issue:8 Topics: Acute Disease; Adult; Ambulatory Care; Clozapine; Haloperidol; Hospitalization; Humans; Male; Psychi	1991
Prevalence of neuroleptic-induced dystonia in mania and schizophrenia. The American journal of psychiatry, 1990, Volume: 147, Issue:9 Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug	1990
Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients. Acta psychiatrica Scandinavica, 1990, Volume: 82, Issue:6 Topics: Activities of Daily Living; Acute Disease; Adult; Antipsychotic Agents; Dopamine beta-Hydroxylase; D	1990
Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. Psychopharmacology, 1990, Volume: 102, Issue:4 Topics: Acute Disease; Adolescent; Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Mal	1990
Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems. Biological psychiatry, 1990, Jun-01, Volume: 27, Issue:11 Topics: Acute Disease; Adolescent; Adult; Brain; Haloperidol; Humans; Infusions, Intravenous; Male; Neurocog	1990
Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients. Neuropsychobiology, 1989, Volume: 22, Issue:3 Topics: Acute Disease; Adult; Dose-Response Relationship, Drug; Haloperidol; Humans; Luteinizing Hormone; Ma	1989
Treatment of acute nonspecific delirium with i.v. haloperidol in surgical intensive care patients. Acta anaesthesiologica Belgica, 1989, Volume: 40, Issue:3 Topics: Acute Disease; Aged; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; Male; Postoperat	1989
Severe hypotension associated with concurrent clonidine and antipsychotic medication. The American journal of psychiatry, 1985, Volume: 142, Issue:2 Topics: Acute Disease; Aged; Antipsychotic Agents; Chlorpromazine; Clonidine; Drug Interactions; Drug Therap	1985
Acutely psychotic patients: a treatment approach. Southern medical journal, 1985, Volume: 78, Issue:7 Topics: Acute Disease; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Combined Modality Therapy; Do	1985
[Prediction of therapeutic success in acute neuroleptic treatment: results of an empirical study of 243 inpatient-treated schizophrenic patients]. Fortschritte der Neurologie-Psychiatrie, 1985, Volume: 53, Issue:10 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Haloperid	1985
Depot neuroleptics for acutely psychotic patients. The American journal of psychiatry, 1987, Volume: 144, Issue:8 Topics: Acute Disease; Antipsychotic Agents; Fluphenazine; Haloperidol; Humans; Psychotic Disorders	1987
Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. The American journal of psychiatry, 1988, Volume: 145, Issue:5 Topics: Acute Disease; Adolescent; Aggression; Akathisia, Drug-Induced; Antipsychotic Agents; Child; Child,	1988
[Chorea rheumatica. Clinico-therapeutic aspects of 13 cases]. Minerva pediatrica, 1988, Volume: 40, Issue:5 Topics: Acute Disease; Adolescent; Anti-Anxiety Agents; Benzodiazepines; Child; Chlorpromazine; Chorea; Fema	1988
[A differential effect profile of neuroleptic therapy of acute schizophrenic patients? Results of a clinico-naturalistic study]. Der Nervenarzt, 1988, Volume: 59, Issue:12 Topics: Acute Disease; Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Haloperidol; Humans;	1988
Plasma concentrations of haloperidol and prolactin and clinical outcome in acutely psychotic patients. Pharmacopsychiatry, 1988, Volume: 21, Issue:5 Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychot	1988
Treatment of severe, refractory agitation with a haloperidol drip. The Journal of clinical psychiatry, 1988, Volume: 49, Issue:6 Topics: Acute Disease; Cerebral Infarction; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; M	1988
Clonidine in the treatment of Tourette's syndrome exacerbation due to haloperidol withdrawal. The Journal of nervous and mental disease, 1986, Volume: 174, Issue:4 Topics: Acute Disease; Adult; Clonidine; Haloperidol; Humans; Male; Substance Withdrawal Syndrome; Tourette	1986
Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. Journal of clinical psychopharmacology, 1987, Volume: 7, Issue:3 Topics: Acute Disease; Adult; Benztropine; Drug Therapy, Combination; Dystonia; Female; Haloperidol; Humans;	1987
Droperidol and acute psychosis. Journal of clinical psychopharmacology, 1987, Volume: 7, Issue:3 Topics: Acute Disease; Droperidol; Haloperidol; Humans; Psychotic Disorders	1987
Bromocriptine in the treatment of neuroleptic-resistant schizophrenia. Biological psychiatry, 1986, Volume: 21, Issue:5-6 Topics: Acute Disease; Adult; Bromocriptine; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans	1986
Intravenous haloperidol in the treatment of acute psychosis. The American journal of psychiatry, 1986, Volume: 143, Issue:10 Topics: Acute Disease; Adult; Haloperidol; Humans; Injections, Intravenous; Middle Aged; Psychotic Disorders	1986
Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? The American journal of psychiatry, 1986, Volume: 143, Issue:5 Topics: Acute Disease; Adult; Aged; Carbamazepine; Chromatography, Gas; Depression, Chemical; Drug Therapy,	1986
Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacology bulletin, 1985, Volume: 21, Issue:1 Topics: Acute Disease; Haloperidol; Humans; Kinetics; Schizophrenia	1985
[Differential diagnosis of acute extrapyramidal motor disorders in children. A case study]. Psychiatrie, Neurologie, und medizinische Psychologie, 1974, Volume: 26, Issue:8 Topics: Acute Disease; Adolescent; Basal Ganglia Diseases; Diagnosis, Differential; Female; Haloperidol; Hep	1974
Strategies for the treatment of acute psychosis. JAMA, 1974, Sep-30, Volume: 229, Issue:14 Topics: Acute Disease; Alcohol Amnestic Disorder; Cooperative Behavior; Emergencies; Female; Fluphenazine; H	1974
Lithium carbonate, haloperidol, and irreversible brain damage. JAMA, 1974, Dec-02, Volume: 230, Issue:9 Topics: Acute Disease; Adult; Bipolar Disorder; Brain; Brain Diseases; Carbonates; Chronic Disease; Consciou	1974
Rapid control of psychotic excitement states with intramuscular haloperidol. The American journal of psychiatry, 1973, Volume: 130, Issue:10 Topics: Acute Disease; Adult; Age Factors; Aged; Body Weight; Dose-Response Relationship, Drug; Female; Halo	1973
[Effect of haloperidol, chlordiazepoxide and chlormethiazole on Porter-Silber chromogens, glycogen and ammonia content in some organs of rats during acute ethanol intoxication]. Endokrynologia Polska, 1973, Volume: 24, Issue:2 Topics: Acute Disease; Alcoholic Intoxication; Ammonia; Animals; Brain; Chlordiazepoxide; Chlormethiazole; C	1973
Man's tripartite brain and psychosomatic medicine. Psychotherapy and psychosomatics, 1970, Volume: 18, Issue:1 Topics: Acute Disease; Adolescent; Brain; Emotions; Evaluation Studies as Topic; Haloperidol; Humans; Male;	1970
[Delirious reactions in acute pancreatitis]. Nordisk medicin, 1969, Sep-11, Volume: 82, Issue:37 Topics: Acute Disease; Adult; Cerebral Ventriculography; Chlorprothixene; Cholecystectomy; Delirium; Diazepa	1969
[Developmental study on night sleep during episodes of manias or acute depressions]. Revue neurologique, 1969, Volume: 121, Issue:3 Topics: Acute Disease; Adult; Bipolar Disorder; Chlorpromazine; Delirium; Electroencephalography; Female; Ha	1969
[Use of haloperidol in the therapy of acute coronary insufficiency]. Kardiologiia, 1970, Volume: 10, Issue:1 Topics: Acute Disease; Aged; Analgesics; Coronary Disease; Drug Synergism; Haloperidol; Humans; Middle Aged;	1970
[The clinical picture and therapy of alcoholic psychoses in old age]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1970, Volume: 70, Issue:5 Topics: Acute Disease; Apomorphine; Barbiturates; Cerebrovascular Disorders; Delirium; Delusions; Female; Ha	1970
The treatment of acute alcohol intoxication and withdrawal. Current psychiatric therapies, 1970, Volume: 10 Topics: Acute Disease; Adult; Alcoholic Intoxication; Alcoholism; Chlordiazepoxide; Chlormethiazole; Ethanol	1970
[Acute psychotic conditions]. Die Medizinische Welt, 1971, May-08, Volume: 19 Topics: Acute Disease; Diazepam; Haloperidol; Humans; Psychotic Disorders; Tranquilizing Agents	1971
Some observations on the use of lithium carbonate. International journal of neuropsychiatry, 1968, Volume: 4, Issue:1 Topics: Acute Disease; Bipolar Disorder; Haloperidol; Humans; Imipramine; Lithium; Phenothiazines; Schizophr	1968
A survey of endodontic practice amongst Flemish dentists. International endodontic journal, 2002, Volume: 35, Issue:9 Topics: Acute Disease; Analgesics; Anti-Bacterial Agents; Attitude of Health Personnel; Belgium; Bismuth; Ch	2002
Acute interstitial nephritis. JAMA, 1977, Oct-10, Volume: 238, Issue:15 Topics: Acute Disease; Adult; Epoxy Resins; Humans; Male; Nephritis, Interstitial; Paint	1977
17 cases of epoxy resin dermatitis in Shanghai. Contact dermatitis, 1992, Volume: 27, Issue:3 Topics: Acute Disease; China; Chronic Disease; Dermatitis, Allergic Contact; Dermatitis, Occupational; Epoxy	1992
[Sensitizing effect of liquid polysulfide rubber]. Berufs-Dermatosen, 1971, Volume: 19, Issue:5 Topics: Acute Disease; Animals; Dermatitis, Contact; Dermatitis, Occupational; Epoxy Resins; Freund's Adjuva	1971
[Clinical and experimental study of the irritating and sensitizing properties of epoxy resins]. Gigiena truda i professional'nye zabolevaniia, 1973, Volume: 17, Issue:5 Topics: Acute Disease; Administration, Topical; Animals; Dermatitis, Contact; Dermatitis, Occupational; Ecze	1973
[Hygienic evaluation of epoxide compounds intended for use in the water supply]. Gigiena i sanitariia, 1974, Issue:12 Topics: Acute Disease; Animals; Chronic Disease; Epoxy Resins; Female; Filtration; Male; Maximum Allowable C	1974

haloperidol and Acute Disease